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CHAPTER ONE

INTRODUCTION

The enzyme topoisomerase II plays a vital role in the replicative processes of the
cell by relaxing supercoiled DNA via the formation of double-strand breaks. Its essential
nature makes it a promising target for anticancer drugs, particularly because proliferative
cancer cells often must make more frequent use of topoisomerase II than noncancerous
cells do [Deweese and Osheroff, 2009]. Anticancer agents that target topoisomerase II
can either inhibit the enzyme’s activity by catalytic inhibition, or by intercalating into the
DNA and stabilizing the cleavage complex between topoisomerase II and DNA [Nitiss,
2009]. This causes the double-strand breaks formed by topoisomerase II to become
permanent, essentially transforming the enzyme into a potent cellular toxin [Fortune and
Osheroff, 2000]. The xanthine alkaloid caffeine, which is consumed by Americans at an
approximate rate of 150 mg/day, is known to interact with many planar, aromatic
anticancer agents and affect their ability to inhibit topoisomerase II [Traganos, et al.,
1993]. This study seeks to examine how caffeine affects ten selected anticancer agents
and their ability to inhibit topoisomerase II. It is believed that the effectiveness of the
majority of the selected anticancer agents will be inhibited by the addition of caffeine.
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1.1.

Cancer
After the initial stages of embryonic development, most cells in the human body

have differentiated into specific types and functions. Although specialized tissues such
as bone marrow and hair follicles can continue to proliferate throughout adulthood, most
cells develop a system of controls on their growth rate. When cells lose this set of
controls, the formation of tumors can result. Benign tumors result when cells have lost
their growth controls but remain contained by a layer of tissue. On the other hand, if the
cells overgrow in an invasive fashion, they can cause malignant tumors, or cancers
[Chow, et al., 2010].
There are over one hundred distinct cancer types, with separate tumor subtypes
found in specific organs. These cancers are distinct from one another in their tissue of
origin, original cell type, responsiveness to hormonal signals, and method of proliferation
[Hanahan and Weinberg, 2000]. Despite these many differences, however, there are six
common traits thought to be shared by all cancer types. These include increased response
to growth signals, decreased response to growth suppressors, the ability to resist
apoptosis, the ability to replicate themselves indefinitely (immortality), the ability to
recruit blood vessels (angiogenesis), and the ability to invade other tissues (metastasis)–
all of which are thought to arise as the result of genetic instability due to mutations
[Hanahan and Weinberg, 2011]. While the majority of cells in a tumor may not be able
to survive indefinitely, those that do have the ability to grow continuously can cause
increased growth of the cancer in a stem-cell like fashion. When tumor cells are grown
in culture, these “immortal” cells are isolated and can be grown for study for an indefinite
period of time [Freshney, 2010].

2

Cancer is thus a disease of uncontrolled cell proliferation. To obtain this common
feature, cancer cells must typically possess oncogenes which are gain-of-function
mutations of proliferation-regulatory protooncogenes [Zhou, et al., 2014]. The growth of
many cancers is directly linked to sensitivity to a particular hormone that causes
increased growth and proliferation. Many such hormones, such as steroids, estrogen, and
progestins, may stimulate the progression of the cell cycle (typically at G1 phase) and
lead to increased cellular replication rates [Doisneau-Sixou, et al., 2003]. Proceeding
rapidly through the G1 phase, and lacking the tumor-suppressor checkpoints that should
slow the cell cycle, cancer cells more frequently enter the DNA synthesis phase in which
DNA must be replicated in preparation for further division [Chow, 2010]. Due to this
increased rate of cell proliferation and the required associated metabolic processes,
enzymes involved in essential processes like DNA replication are common targets for
anticancer drugs.
1.2.

Topoisomerase II
Inside the cell, DNA exists for much of the time in a tightly wound, supercoiled

state. This is necessary because, in the human body, cells with an average diameter of
only ten micrometers must contain approximately two meters of DNA. Because
replication in normal cells occurs at a speed of roughly two thousand base pairs per
minute per replication fork, it is important that the nucleotides in this supercoiled DNA
can become exposed quickly [Deweese and Osheroff, 2009].

3

Figure 1.1. The enzyme topoisomerase II alpha complexed with double stranded DNA.
PDBid 4FM9. [RSCB PDB, 2012]

For DNA to be replicated or transcribed, it must be unwound enough that the
necessary cellular machinery has access to the base pair sequence. This unwinding is
facilitated by the torsional strain produced by the DNA being appropriately supercoiled.
Enzymes known as topoisomerases change the shape of the DNA without any net altering
of its covalent structure. Type II topoisomerases (shown in Figure 1.1) were discovered
by Martin Gellert in 1976. They are a class of enzymes that create double-strand breaks
in DNA, powered by the hydrolysis of ATP [Fortune and Osheroff, 2000].
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Figure 1.2 Double-strand break formation in DNA mediated by the enzyme
topoisomerase II. Scissile bonds are formed four bases apart, across the major groove of
the double helix. [Deweese and Osheroff, 2009]

The active site of topoisomerase II contains a tyrosine residue that initiates a
nucleophilic attack on a phosphate of the DNA backbone, as shown in Figure 1.2. This
generates a transesterification reaction that results in the enzyme being covalently bonded
to the newly-created 5′ end of the DNA chain (mechanism shown in Figure 1.3). Two
separate enzyme subunits work together as homodimers to produce two scissile bonds
four bases apart on opposite strands of the double helix, located across the major groove
from one another. This reaction is not specific to a single DNA sequence and can act
anywhere along the DNA where the local structure permits binding of the enzymes. This
covalently-bound complex of DNA and enzyme is referred to as the “cleavage complex”
[Deweese and Osheroff, 2009].
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Figure 1.3 Cleavage mechanism of topoisomerase II. The transesterification reaction
and formation of the phosphotyrosyl bond requires two divalent metal ions (such as
Mg2+) [Deweese and Osheroff, 2009].

Class II topoisomerases, such as topoisomerase II, are often used to separate
supercoiled DNA strands in the nucleus. They also function to unwind plasmids, circular
fragments of DNA commonly found in bacterial cells. Topoisomerase II relaxes
supercoiled DNA by forming the double-strand breaks as described above, and then
passing an unbroken region of double-stranded DNA through the resulting gap. This
serves to untangle chromosomes from one another prior to separation during mitosis
[Goodsell, 2006] [McDowall, 2014], or can lower the writhe number (degree of
supercoiling) of a plasmid [Klenin and Langowski, 2000].
Because of the speed with which these unwinding events must occur during the
cellular replication process, it is crucial that these enzymes remain functional and
efficient. If the formation of cleavage complexes in the cell decreases, the rate of DNA
replication or transcription will slow, resulting in a slow growth rate, mitotic failure, and
ultimately cell death. Conversely, if the concentration of cleavage complexes is
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unnaturally increased in the cell, it can lead to unintended recombination events that
result in translocation of DNA segments, mutagenesis and cancer, or apoptosis [Deweese
and Osheroff, 2009].
1.3.

Topoisomerase II as a Target for Anticancer Agents
One of the aforementioned common characteristics of cancer cells was their

increased response to growth signals. This results in an increase in the rate of cellular
proliferation, requiring increased frequencies of DNA replication and transcription into
RNA. It is known that proliferating cells express higher levels of topoisomerase IIα than
quiescent cells [Hengstler, et al., 2002]. Similarly, cancerous cells often make greater use
of the topoisomerase II enzyme than noncancerous cells. As such, topoisomerase II is a
common target for anticancer drugs [Deweese and Osheroff, 2009] [Goodsell, 2006].
There are two main categories of inhibition of the topoisomerase II enzyme, as
illustrated in Figure 1.4. The first, and more common, involves utilizing the enzyme’s
cleavage mechanism to essentially transform it into a “potent cellular toxin” [Fortune and
Osheroff, 2000]. Topoisomerases are essential yet vulnerable enzymes, and can be
effectively converted into DNA-cleaving nucleases by “topoisomerase poison” anticancer
agents, oxidative stressors, or even acidic pH. The resulting DNA cleavage can lead to
genomic instability and cell death [Li and Liu, 2001]. Under normal conditions, the
strand breaks formed by the topoisomerase complex are temporary, and the presence of
low concentrations of the cleavage complex is usually tolerated by the cell. However,
high concentrations of double-strand breaks signal the apoptotic cellular mechanisms
associated with serious DNA damage [Baldwin and Osheroff, 2005]. In this way,
stabilization of the “strand-passing intermediate” cleavage complex induces cell death by
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causing the topoisomerase itself to act as a poison. While drugs that trigger the
topoisomerase poison mechanism have a better anticancer activity than those that utilize
the alternate method, topoisomerase poisons are also much more cytotoxic than their
inhibitory counterparts. Evidence that DNA damage is due to topoisomerase-mediated
strand breakage can be observed by extracting the DNA from a cell treated with a
topoisomerase poison and revealing the topoisomerase subunits still covalently attached
to the cleavage site [Huang, et al., 2001].

Figure 1.4. Mechanism of topoisomerase II inhibition by various anticancer agents.
Anticancer agents such as aclarubicin prevent topoisomerase II from binding the initial
fragment of DNA, the G-segment or “gate.” The T-segment, or “transport” DNA is
captured, but will not be passed through unless double-stranded breaks are created in the
G-segment. This cleavage can be inhibited by a catalytic inhibitor such as merbarone.
Conversely, topoisomerase poisons such as etoposide allow the cleavage of the Gsegment, but stabilize the cleavage complex to prevent religation. Finally, ICRF-187 acts
after T-segment pass-through and inhibits ATP hydrolysis and strand dissociation,
preventing the catalytic cycle from beginning again [Nitiss, 2009].
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The second method of inhibition often utilized by anticancer agents is the route of
catalytic inhibition. This can entail a variety of mechanisms, from interfering with
topoisomerase II’s ability to bind DNA, stabilizing noncovalent complexes between the
enzyme and DNA, or inhibiting the ability of topoisomerase II to bind ATP. Drugs that
utilize catalytic inhibition of topoisomerase can be utilized for more than just their
antitumor properties, and can function as cardioprotectors or potentiators for other
antineoplastic agents [Larsen, et al., 2003]. This method of topoisomerase inhibition is
much less cytotoxic than the topoisomerase poison route, because, while catalytic
function of the enzyme is inhibited, no permanent DNA lesions are formed [Huang, et al.,
2001]. While chemotherapy regimens continue to be developed that target the catalytic
activity of the topoisomerase II enzyme, drugs that utilize the “poison” route are still
much more common [Nitiss, 2009].
Unfortunately, the extreme variability in cancer types means that no one treatment
method is guaranteed to be effective on a particular type of cancer. Many different
cancers have different levels of topoisomerase II expression, and thus have different
levels of sensitivity to drugs that target that enzyme [Cole, et al., 1991]. For example,
there are low levels of expression for the topoisomerase II gene in lung cancers
[Giaccone, et al., 1992]. In studies of childhood acute lymphoblastic leukemia, there
have been shown to be as many as 6  104–7 x 105 topoisomerase IIα monomers in Raji
cells from a Burkitt’s lymphoma, while resting human peripheral blood lymphocytes
were found to have no detectable levels of topoisomerase II α expression [Padget, et al.,
2000]. Similarly, some other cancers have been shown to be resistant to topoisomerase
II-targeting anticancer drugs such as etoposide. KB cells have lower levels of
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topoisomerase II expression, so there are fewer enzymes to harm the cell by forming
permanent double-strand breaks; however, the topoisomerase enzymes that are present
have a higher activity due to their phosphorylated serine residues which makes the
overall level of topoisomerase activity under untreated circumstances equal to that in
noncancerous cells [Takano, et al., 1991].
Another factor to consider is the physical location of the topoisomerase II gene in
the genome. In HER-2-sensitive breast cancer, the mutated erbB-2 oncogene is
physically close to the gene for the topoisomerase IIα subunit. When the erbB-2 gene is
amplified, some cancer lines show increased topoisomerase IIα amplification, while other
lines show a deletion [O’Malley, et al., 2009] [Smith, et al., 1993] [Jarvinen, et al., 2000].
These changes in gene expression can greatly alter the efficacy of drugs which utilize the
topoisomerase enzyme as the source of the lethal DNA damage. Specifically, patients
diagnosed with breast cancer bearing coamplification of the HER2 and topoII genes
showed an increased response to doxorubicin chemotherapy, while cases without the
amplification of either gene showed a significantly decreased response rate.
Amplification of HER2 alone produced only an intermediate response rate, indicating that
variability in the topoII expression levels plays a role in a cancer’s sensitivity to
chemotherapy [Park, et al., 2003]. This exemplifies why it is important to learn as much
as possible about a specific case of cancer before assigning a chemotherapeutic regimen.
It is also important to note that, while the topoisomerase-inhibiting effects of the
wide variety of anticancer agents represent large benefits for the medical community, use
of these compounds is not without risk. Multiple studies have suggested that the
administration of topoisomerase-inhibiting drugs and the dietary consumption of natural
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topoisomerase II poisons by expectant mothers can lead to a ten-fold greater risk for
infant leukemia [Ross, et al., 1996] [Hengstler, et al., 2002]. Similarly, the potential for
improper recombination events resulting from DNA repair mechanisms acting upon the
topoisomerase-cleaved DNA strands may cause further mutagenesis and lead to the
potential development of secondary cancers.
1.4.

Anticancer Agents
Figure 1.5 shows the structures of the anticancer agents selected for this study.

Figure 1.5. Structures of anticancer agents used in present study.
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1.4.1. Doxorubicin
An often prescribed anticancer agent, doxorubicin (shown in Figure 1.6) is
known to intercalate into DNA and inhibit the action of topoisomerase II
[Pommier, et al., 2010]. It was created by Italian researchers who, having isolated
daunorubicin from the soil bacteria Streptomyces peucetius in the 1950s, wanted
to synthesize a compound with similar anticancer properties but with lower
cardiotoxicity. The antibiotic isolated from their mutated form of the bacteria,
doxorubicin, proved to have even stronger anticancer activity against tumors in
mice, although the toxic effects on the heart remained strong [The Myeloma
Beacon, 2008].
Doxorubicin is known to cause single- and double-stranded breaks in
DNA by its interaction with the enzyme topoisomerase II. When the broken
fragments of DNA are extracted, subunits of the topoisomerase II protein remain
covalently bonded to the DNA at the site of the broken phosphodiester bonds,
indicating that the mechanism of DNA damage was due to the stabilization of the
DNA-topoisomerase II cleavage complex intermediates [Tewey, et al, 1984].
Interestingly, the sites at which doxorubicin stabilizes the topoisomerase II
cleavage complexes to induce double-stranded breaks are separate from those
where the topoisomerase II enzyme alone typically cleaves DNA. The exclusivity
of the two sets of sites on the DNA revolves around the need for doxorubicinstabilized cleavage sites require a 3′-A residue, and cleavage sites for
topoisomerase alone never involve a 3′-A [Capranico, et al., 1990]. Although
doxorubicin typically is administered as an independent drug to function as a
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topoisomerase IIα poison, in vivo it may also interact with the non-toxic levels of
formaldehyde released by co-administered prodrugs to form toxic doxorubicinDNA adducts that are more cytotoxic than the DNA lesions caused by
topoisomerase II and doxorubicin [Swift, et al., 2006].
Doxorubicin is currently used to treat leukemias; solid tumors, and
lymphomas [Swift, et al., 2006] as well as many other tissue-specific cancers such
as breast, ovarian, and hepatocellular carcinomas. Unfortunately, doxorubicin
incurs a wide variety of negative side effects, the most damaging of which is
cardiotoxicity, which frequently leads to congestive heart failure [Chen, et al.,
2011]. These side effects may become worse if doxorubicin is administered in
conjunction with other medications, such as the popular anticancer drug paclitaxel
[Jassem, et al., 2001].
Due to the staining method employed in this experiment, it is relevant to
note that doxorubicin is a competitive inhibitor of the DNA intercalation sites for
the fluorescent dye ethidium bromide [Xie, et al., 2003] (DNA intercalation
shown in Figure 1.7). As such, DNA that has been previously intercalated with
doxorubicin may exhibit poor fluorescence following staining with ethidium
bromide and subsequent ultraviolet excitation.
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Figure 1.6. Doxorubicin.

Figure 1.7. Two morpholino doxorubicin molecules bound to d(CGTACG).
Doxorubicin, with one attached morpholinyl moiety on the amino sugar, intercalates
along the plane of the bases of the double-stranded DNA. Intercalation into the DNA is
not affected by the morpholinyl moiety. PDBid 2DES [RSCB PDB, 1993].
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1.4.2.

Tingenone
Tingenone (Figure 1.8) is a triterpene quinone-methide found in the bark

of a species of the genus Salacia from Monteverde, Costa Rica [Setzer, 2000],
Euonymus tingens [Brown, et al, 1973], and others. It has shown strong
cytotoxicity against multiple cell lines [Gomes, et al., 2011]. Tingenone is
currently used to treat skin cancer in humans because it causes low levels of
irritation to the surrounding tissue. Tingenone has been shown to weakly inhibit
topoisomerase activity [Brinker, et al., 2007]. Molecular docking studies suggest
that tingenone binds to DNA in a non-intercalative fashion, and is expected to act
as a topoisomerase II catalytic inhibitor rather than a topoisomerase II poison
[Setzer, 2008].

Figure 1.8. Tingenone.
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1.4.3. Paclitaxel
Paclitaxel (Figure 1.9) was discovered in the early 1960s in extracts of the
bark of Taxus brevifolia, the Pacific yew tree. The active component was isolated
in 1969, and clinical trials began and the late 1970s. Paclitaxel was originally
prescribed as a treatment for ovarian cancer, but its use has since expanded to
treat a wide variety of cancers including head, neck, lung, bladder, and esophageal
cancers [Donehower, 1996].
While commonly used in chemotherapy regimens, paclitaxel can have
variable effects on the topoisomerase II enzyme. Low concentrations (0.02-500
nM) can stimulate the catalytic activity of topoisomerase II, while higher
concentrations (greater than 5 µM) inhibit activity. It has been shown that
paclitaxel acts directly on the topoisomerase II enzyme, rather than intercalating
into the DNA or acting on the DNA-topoisomerase complexes [Dhawan and
Swaffar, 1999].

Figure 1.9. Paclitaxel.
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1.4.4. Alkaloids
1.4.4.1.

Berberine

Berberine (Figure 1.10) is a protoberberine alkaloid that has been isolated
from a wide variety of plants around the world. One such plant, Berberis
fremontii, has been used in traditional Native American medicine [Stermitz, et al.,
2000] to treat diarrhea and scorpion bites [Suess and Stermitz, 1981], while
isolates from another plant in China, Coptis chinensis, have been used to treat
bacteria-induced diarrhea since the 1950s [Kong, et al., 2004].
Berberine has been shown to have weak or no activity as a topoisomerase
poison at concentrations of 10 mM or 40 mM, and intercalate only weakly and
non-specifically [Park, et al., 2004] [Kim, et al., 1998] into the minor groove of
the double-stranded DNA (shown in Figure 1.11). This leads to morphological
changes in and fragmentation of the DNA between nucleosomes, which then
trigger an arrest of the cell cycle and apoptosis [Kuo, et al., 1995]. Despite
assertions that berberine has no antitumor activity [Kim, et al., 1998], other
studies show that berberine can reduce both tumor size and incidence for tongue
cancer and doses of 10 mg/kg [Ho, et al., 2009], and has antitumor activity against
cervical, colonic, esophageal, oral, and prostate cancers, as well as leukemia,
melanoma, and glioblastoma. Also, berberine has also been shown to inhibit
normal osteoblast cells to a lesser extent than osteosarcoma cells, which is a
desirable quality for an anticancer treatment [Liu, et al., 2009]. Concentrations of
10 µg/mL berberine have been shown to induce apoptosis, while concentrations
of 50 µg/mL–100 µg/mL show the intercalation of berberine into DNA, the
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formation of double-stranded DNA breaks, and the inhibition of DNA synthesis,
followed by cell death [Letasiova, et al., 2005].

Figure 1.10. Berberine.

Figure 1.11. Berberine bound to DNA d(CGTACG). Berberine intercalates along the
plane of the bases of the double-stranded DNA. PDBid 3NP6 [RSCB PDB, 2011, a].
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1.4.4.2.

Chelerythrine

Chelerythrine (shown in Figure 1.12) is a quaternary benzophenanthridine
alkaloid that has been extracted from the Asian herb Chelidonium majus, among
others. Many plants that contain these compounds have been used in Chinese
herbal medications to treat cancer. Chelerythrine is a known DNA intercalator
(shown in Figure 1.13), with a particularly high binding affinity for the specific
double-stranded DNA sequence 5′-TGGGGA-3′ / 3′-ACCCCT-5′ (Kd < 1  10-6
M) [Bai, et al., 2006]. Chelerythrine has shown strong antitumor activity across
many cell lines with minor toxicity to systemic tissues [Chmura, et al., 2000],
which may be due to its ability to inhibit the enzyme protein kinase C (PKC)
[Herbert, et al., 1990]. It has not been shown to inhibit topoisomerase II, but was
of interest to this study as a potent DNA intercalator and anticancer agent.

Figure 1.12. Chelerythrine
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Figure 1.13. Chelerythrine bound to DNA d(CGTACG). Chelerythrine intercalates
along the plane of the bases of the double-stranded DNA. PDBid 4D9Y [RSCB PDB,
2013].

1.4.4.3.

Sanguinarine

Sanguinarine (Figure 1.14) is also a benzophenanthridine alkaloid, and an
analogue of chelerythrine. It is obtained from the roots of the poppy-like flower
Sanguinaria canadensis, which has been used in traditional Native American
medicines. Sanguinarine not only acts as an antioxidant, anti-inflammatory, and
antimicrobial drug, but also stops cellular proliferation much more effectively in
cancerous cells than in normal cell types [Holy, et al., 2006]. pH-dependent
structural changes in sanguinarine allow it to bind to DNA by intercalation,
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particularly to GC-rich regions such as d(TGCGCA)2 (Ka ~ 6  105 L/mol) [Bai,
et al., 2006] (intercalation shown in Figure 1.15). As an anticancer agent,
research has shown that 5—10 µM concentrations of this drug can cause the cell
cycle to halt during the growth phase, and also cause topoisomerase II to
relocalize from the nucleus into the cytoplasm without causing apoptosis [Holy, et
al., 2006] [Malikova, et al., 2006].

Figure 1.14. Sanguinarine.
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Figure 1.15. Sanguinarine bound to DNA d(CGTACG). Sanguinarine intercalates along
the plane of the bases of the double-stranded DNA. PDBid 3NX5 [RSCB PDB, 2011, b].

1.4.4.4.

Ellipticine

Another plant alkaloid with strong antitumor activity is ellipticine (Figure
1.16), which was first isolated in Florida in 1959 from the leaves of Ochrosia
elliptica and has since been obtained from a variety of other species [Kansal and
Potier, 1986].
Ellipticine preferentially binds helical DNA by intercalation (shown in
Figure 1.17), as shown by increased sedimentation and viscosity of the bound
DNA fragments, decreased supercoiling of closed circular DNA, and electric
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dichroism measurements, which show that the ellipticine orients parallel to the
plane of the DNA bases [Kohn, et al., 1975]. The primary target of ellipticine is
topoisomerase II, and although ellipticine may bind the topoisomerase/DNA
complex (Kd ~ 1.5 µM), it also binds the enzyme in the absence of DNA. This
implied direct interaction between topoisomerase II and ellipticine induces DNA
damage by enhancing the rate at which the enzyme cleaves double-stranded DNA,
without inhibiting the topoisomerase-mediated DNA religation [Froelich-Ammon,
et al., 1995]. Ellipticine has been shown to inhibit several breast adenocarcinoma,
leukemia, neuroblastoma, and glioblastoma cell lines. Other methods by which
ellipticine induces cellular damage and apoptosis involve the creation of cytotoxic
free radicals, initiating mitochondrial apoptosis, and the generation of covalent
DNA adducts–the formation of which is dependent on ellipticine being activated
by cytochrome P450 or peroxidases [Stiborova, et al., 2011]. Once activated,
ellipticine may covalently bond directly to DNA. Although ellipticine is a potent
mutagen, it is still frequently utilized during chemotherapeutic regimes due to its
high efficiency in treating several types of cancer, few toxic side effects, and the
fact that it shows no hematological toxicity [Aiomva, et al., 2007].

Figure 1.16. Ellipticine.
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Figure 1.17. Ellipticine in complex with 6bp DNA. Two ellipticine molecules
intercalating into double-stranded DNA. PDBid 1Z3F [RCSB PDB, 2005 b].

1.4.5. Anthocyanidins
Most flowers and fruits that bear a red, purple, or blue color do so due to a
family of water-soluble pigments in the flavonoid and polyphenol families called
anthocyanins. These compounds are found commonly in bilberries, black currant
berries, cranberries, blackberries, blueberries, lingonberries [Mirtoselect, 2014],
grapes, blood oranges, black soybeans, rice, beans, red onions, potatoes, cabbage
[Bei, et al., 2009], and more. Anthocyanins are planar molecules with three
aromatic rings, which are covalently bonded to monosaccharides, most commonly
glucose. The aglycon groups without the attached sugar moiety are referred to as
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anthocyanidins (common structure shown in Figure 1.18). While the
anthocyanidins are sometimes thought of simply as degradation products of the
anthocyanins, they possess a number of beneficial properties [Mirtoselect, 2014].
Currently, at least eighteen anthocyanidins are used in foods, cosmetics, and
pharmaceuticals [Cretu, et al., 2013].
Anthocyanidins have been shown to have chemopreventative properties
against a variety of cancers [Lamy, et al., 2008], often acting by interfering with
the action of topoisomerase I and II enzymes. Because many anthocyanidins may
interfere with multiple signaling cascades associated with cell proliferation, the
risks of ingesting large quantities of these compounds must be weighed against
their many benefits. Also, at concentrations of greater than 50 µM, many
anthocyanidins alone can cause double-stranded breaks in DNA due to their
strong affinity for binding double-stranded DNA [Habermeyer, et al., 2005].
1.4.5.1.

Malvidin

Malvidin is an anthocyanidin obtained from red grape skin and red wine.
It has been shown to inhibit tumor growth [Quintieri, et al., 2013] by inhibiting
topoisomerase II, as well as the cellular messenger molecule cyclicAMP (cAMP)
and the enzyme phosphodiesterase [Jo, et al., 2005].
1.4.5.2.

Delphinidin

The anthocyanidin delphinidin is found in bilberries, blueberries,
eggplants, and hibiscus flowers, among other plants. Along with cyanidin,
delphinidin is cytotoxic to metastatic colorectal cancer cell lines LoVo and
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LoVo/ADR, and can inhibit the growth of multiple breast cancer cell lines
[Norton, 2011].
Delphinidin has been shown to inhibit both topoisomerase I and II, but
does not do so by stabilizing the DNA-topoisomerase II intermediate state.
Instead, it inhibits the catalytic activity of topoisomerase II [Habermeyer, et al.,
2005]. Delphinidin acts as a chemopreventative agent by inhibiting both tumor
growth and angiogenesis, in vitro and in vivo, by inhibiting tyrosine
phosphorylation, although this is suspected to be due to targeting of the vascular
endothelial growth factor receptor and platelet-derived growth factor receptor-β
[Lamy, et al., 2008]. It has also been shown to interact with other anticancer
agents such as doxorubicin and etoposide, decreasing the number of
topoisomerase IIα/DNA cleavage complex intermediates and reducing their
DNA-damaging chemotherapeutic properties at concentrations lower than 10 uM
[Esselen, et al, 2009].
1.4.5.3.

Cyanidin

Cyanidin is the most widespread anthocyanidin found in nature [Bei, et al.,
2009], commonly isolated from blackberries and blackcurrant. It does not act as a
topoisomerase poison by stabilizing the DNA-topoisomerase intermediate
complex [Habermeyer, et al., 2005]. Instead, it has been reported that, of the
anthocyanidins, only delphinidin and cyanidin can serve as topoisomerase I and II
catalytic inhibitors due to the hydroxyl groups adjacent to their B-ring [Jo, et al.,
2006]. It also may interfere with the effects of other anticancer drugs being
administered concurrently [Esselen, et al., 2011].
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Due to the structural similarities between delphinidin and cyanidin, and
the fact that neither is shown to affect the cleavage complex, cyanidin was not
chosen for full testing.
1.4.5.4.

Pelargonidin

Another of the most abundant anthocyanidins, pelaragonidin is found in
red fruits such as strawberries and pomegranates [Seeram, et al., 2006]. Along
with cyanidin, pelargonidin can combat the genotoxicity of multiple DNA
damaging environmental toxins (at dosage levels of 2.5–20 mg/kg in mice)
[Khandelwal and Abraham, 2014].
Currently, no studies have shown that pelargonidin is able to either inhibit
the catalytic activity of topoisomerase II or stabilize the DNA/topoisomerase II
cleavage complex. However, due to structural similarities to other inhibitory
anthocyanidins such as malvidin and delphinidin, it was decided to include
pelargonidin in this experiment.

Anthocyanidin
Delphinidin
Cyanidin
Pelargonidin
Malvidin

R1
OH
OH
H
OCH3

R2
OH
H
H
OCH3

Figure 1.18. Common structure of anthocyanidins.
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1.5.

Caffeine
Caffeine, or 1,3,7-trimethylxanthine (Figure 1.19), is a common component of

coffee, tea, sodas, and chocolate [Davies, et al., 2001]. The average American consumes
approximately 150 mg of caffeine each day. An 8 oz. cup of coffee contains 100 mg of
caffeine, while a cup of tea contains 35 mg and a serving of a soft drink typically contains
25 mg of caffeine. The consumption of five cups of coffee (considered a moderate daily
consumption level) results in an average plasma caffeine concentration of 26 µM
[Arendash and Cao, 2010]. As such, caffeine can be considered one of the most widely
consumed drugs in the United States, whose effects depend on dosage level and target
cell type [Traganos, et al, 1993]. At concentrations around 5 mM, caffeine has little or no
effect on cellular growth or cell cycle progression. However, at concentrations of 10 mM
and above, it has been shown to prolong the cell’s G1 phase, inhibit enzymes that are
needed for synthesizing DNA, and cause increased condensation of chromatin [Traganos,
et al., 1991]. Also, of critical importance to this study, caffeine has been shown to act as
a topoisomerase II inhibitor itself. Concentrations of 99 mM (in water) or 145 mM (in
serum-free medium) caffeine were shown to inhibit the decatenating activity of
topoisomerase II [Shin, et al., 1990].
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Figure 1.19. Caffeine.

Because of its planar, aromatic structure, caffeine has been shown to have a
variety of reactions with various drugs–specifically, other compounds that also have
planar, aromatic structures. Caffeine has been shown to intensify the effects of various
molecules, such as alkylating compounds, analogues of cisplatinum, and hydroxyurea. It
can even intensify the effects of ionizing radiation. This is believed to be due to
caffeine’s interference with the cell’s DNA repair mechanisms, or its ability to limit the
cell’s repair time [Traganos, et al., 1993]. Of particular interest to this study, caffeine has
been shown to reduce the effectiveness of many aromatic, intercalating topoisomerase
inhibitors. For example, treating L1210 cells with 0.5 µg/mL doxorubicin can reduce cell
growth to 26% of the control, while combining this treatment with 5 mM caffeine
resulted in 65% cell growth relative to controls. Similarly, an hour of treatment with 5
µg/mL ellipticine can reduce cell growth to 20% of control, while simultaneous addition
of 5 mM caffeine resulted in only 42% cell growth relative to controls, and subsequent
addition of caffeine restored growth levels to 60% of control [Traganos., et al, 1991].
Other anticancer DNA-intercalating agents which are inhibited by the addition of caffeine
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include actinomycin D, daunomycin, ethidium bromide [Davies, et al., 2001], ellipticine,
and mitoxantrone. Caffeine has also been recorded as reducing the effects of nonintercalating topoisomerase I inhibitors, such as camptothecin and topotecan [Traganos,
et al., 1993].
The inhibitory effects of caffeine on the aforementioned drugs are greatest when
applied simultaneously, or within one hour, of drug administration [Traganos, et al.,
1991]. Preincubation with caffeine, or addition of caffeine more than three hours after
application of the drug, shows no effect on the function of the drugs. While this was
believed to support the hypothesis that there is a direct interaction between the drug and
the caffeine molecule [Traganos, et al., 1993], the kinetics of the enzymatic reactions
involved calls the relevance of this information into question.
NMR analysis shows that, in aqueous solution, caffeine is capable of binding to
DNA with the same affinity with which it binds to the DNA intercalating agents (Kd ~
0.001–0.01 M), which is significantly lower than the affinity with which anticancer drugs
such as doxorubicin bind to the DNA (Kd ~ 10-5–10-6 M) [Evstigneev, et al., 2006]. In
the present study, concentrations of anticancer agents used range from 1.65 nM–2.03 mM
in assay, while concentrations of caffeine ranged from 165 nM–50 mM in assay, allowing
the observation of the separate compounds at concentrations relative to their respective
Kd values. However, research indicates that, in many cases, caffeine binds directly to the
anticancer agents, preventing them from intercalating into the DNA and subsequently
inhibiting the topoisomerase II enzyme. This effectively reduces the concentration of
free drugs in the cell, and lessens the deleterious effects on the cell caused by the creation
of a “poisonous” topoisomerase. This method of interaction is referred to as the
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“interceptor” model, rather than the “protector” model–indicating that caffeine protects
the cell by intercepting the drug molecule before it can interact with the DNA or
topoisomerase, rather than interacting directly with the DNA or topoisomerase itself
[Traganos, et al., 1993] [Traganos., et al, 1991]. However, because the high
concentrations of caffeine required to observe an interaction between the caffeine and the
anticancer agents are similar to the concentration range at which caffeine will bind to the
DNA itself (similar dissociation constant range), it is possible that the caffeine’s
interaction with the DNA will block sites on the DNA where the drugs would typically
intercalate. This would allow the protector model to play a secondary role in reducing
the efficacy of DNA-intercalating anticancer drugs [Evstigneev, 2006].
Spectrophotometric analysis has confirmed the direct mode of interaction between
caffeine and the intercalative compounds. Spectrophotometric shifts in the absorption
spectrums of aromatic anticancer drugs outside the absorption range of caffeine (> 350
nm) are consistent with the exothermic formation of stacking complexes and the
subsequent sequestration of the anticancer agents and the lowering of their free
concentration in solution [Traganos, et al., 1993]. Several aromatic DNA intercalators
absorb and emit visible light during spectrophotometric testing. The excitation arising
from the π—π interactions of the binding between titrated caffeine and 10 µM
intercalators such as ethidium bromide or acridine orange causes the local solvent
environment to become more hydrophobic, which results in a red-shift of the absorption
and emission spectra (as shown in Figure 1.20). Also, because water is an effective
quencher molecule, the exclusion of water from the complex induces a longer
fluorescence lifetime than from the excited intercalators alone. Therefore, experimentally
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observed increases in fluorescence yield and lifetime, as well as the lower-energy
spectrophotometric shift resulting from the excited π–π* state, support direct binding
between caffeine and many DNA intercalators [Larsen, et al., 1996]. However, these
same studies often do not research the existence of a corresponding effect on these
intercalators to actually intercalate into DNA in the presence of caffeine, or whether this
has any effect on their ability to inhibit enzymes like topoisomerase II.

Figure 1.20. Light absorption spectrum of 37 µM topotecan, alone (solid line) and in
solution with 10 mM caffeine (dotted line). Expressed as a function of molar absorption
coefficients (M-1 cm-1) [Traganos, et al., 1993, used with permission].

Recent analysis regarding the interactions between caffeine and planar, alkaloid
antitumor agents has also supported the direct interaction between caffeine and drug.
Following cytotoxicity studies with MCF-7 breast cancer cells that confirmed the
inhibitory effects of caffeine on the effectiveness of the anticancer drugs, molecular
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modeling using density functional theory and M06 functional modeling were used to
demonstrate the affinity of the caffeine molecule for binding directly to the drugs. The
proposed strong π—π interaction energies also supported the “interceptor” model of drug
inhibition, rather than the “protector” model [Hill, et al., 2011]. For example,
doxorubicin and caffeine were found to be most likely to dock in an orientation which
allowed for an overlap of their molecular orbitals, strong electrostatic interactions, and
90o dipole moments, although other potential docking orientations would also support an
interaction between the two compounds. The interaction energy of the lowest-energy
orientation between doxorubicin and caffeine was shown to be -15.86 kcal/mol in
aqueous solution, with the resulting orientation shown in Figure 1.21. Similarly, studies
with ellipticine revealed that the interaction energy of caffeine and ellipticine was -11.02
kcal/mol in aqueous solution. The most probable interaction formation between
ellipticine and caffeine is shown in Figure 1.22 [Hill, 2011].
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Figure 1.21. Caffeine in complex with doxorubicin [Hill, 2011, used with permission].

Figure 1.22. Caffeine in complex with ellipticine [Hill, 2011, used with permission].

1.6.

Basis for Current Study
While the fact that caffeine can inhibit the action of DNA intercalators has been

well-established, previous studies have also indicated that the effects of some natural
products on topoisomerase II may be potentiated, rather than inhibited, by the addition of
caffeine [Moriarity, personal discussion, 2013]. In fact, the effects of the popular
anticancer agent etoposide, which catalytically inhibits the topoisomerase II enzyme, are
made stronger by the addition of caffeine [Lock, et al., 1994].
Currently, caffeine may be used during chemotherapeutic regimens to prevent
overdose, or to lessen the negative side effects of anticancer drugs. The advantage of
using caffeine to mitigate the effects of anticancer agents lies in the fact that the
concentration range at which it affects many drugs is much lower than the range at which
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caffeine induces its own harmful effects against the cell [Traganos, et al., 1993]. Due to
the potential variability of the responsiveness of different drugs to the addition of
caffeine, the frequency at which many Americans consume caffeine on a daily basis, and
the differences in effectiveness of topoisomerase II-targeting drugs on different types of
cancers, the potential interactions between anticancer agents chosen for chemotherapy
and popularly-consumed dietary components such as caffeine should be well understood.
If the drugs utilized are those whose effects are potentiated by the addition of caffeine,
rather than reduced, then administering caffeine during a suspected overdose would be
very dangerous. Alternately, if there are known effective drugs whose effects are
enhanced by the addition of caffeine, it would allow for lower concentrations of drugs to
be administered alongside caffeine for the same level of activity, reducing cost and the
potential for overdose.
This study will expand upon previous research that examined DNA-intercalating
alkaloids and how their interaction with caffeine affects their ability to inhibit the activity
of topoisomerase II [Hill, 2011]. By using gel based assays that allow for indirect
observation of the activity of topoisomerase II, the effects of various anticancer agents
alone, in the presence of caffeine, and in combination will be recorded. This study seeks
to examine how caffeine affects ten selected anticancer agents and their ability to inhibit
topoisomerase II. It is believed that the action of the majority of the selected anticancer
agents will be inhibited by the addition of caffeine.
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CHAPTER TWO

EXPERIMENTAL

This chapter details the materials and procedures utilized in performing
topoisomerase II inhibition assays, including assay optimization, determination of the
lowest inhibitory concentrations of various anticancer agents, observation of the effects
of caffeine, and densitometry analysis.
2.1 Materials and Instruments
Human recombinant topoisomerase IIα, produced by E. coli, was purchased from
Affymetrix Inc. / United States Biochemical Corporation (Cleveland, OH).
pBR322 plasmid DNA isolated from E. coli was purchased from Thermo
Scientific (Waltham, MA).
Etoposide and dimethylsulfoxide (DMSO, ≥ 99.5% pure) were obtained from
Sigma-Aldrich (St. Louis, MO). Anticancer agents berberine, chelerythrine, doxorubicin,
sanguinarine, paclitaxel, delphinidin, malvidin, and pelargonidin were previously
obtained from Sigma-Aldrich by researchers at the University of Alabama in Huntsville,
Huntsville, AL, and diluted to 1% (w/v) solutions in DMSO.
Tingenone was previously obtained by researchers at the University of Alabama
in Huntsville, Huntsville, AL.
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Ellipticine was obtained from Tocris Bioscience (Bristol, UK).
Lambda bacteriophage DNA Hind III digest, for use as a DNA molecular size
marker, was obtained previously from Research Genetics (Huntsville, AL).
Agarose (low electroendosmosis, electrophoresis grade) was obtained previously
from Fisher Scientific (Pittsburgh, PA).
All other chemicals used were analytical reagent grade.
The most commonly used instruments were a gel electrophoresis apparatus with
attached FotoForce 120 power source (FOTODYNE) and the Kodak EDAS 290 Gel
Imager / UV transilluminator (312 nm, 20.5 cm x 28 cm, Fisher Scientific). Software
used was the Kodak 1D image analysis software for image acquisition and
MYImageAnalysis densitometry software (version 1.1, trial version, build 753, Thermo
Scientific).
2.2 Topoisomerase II Inhibition Assay
As reviewed in chapter 1, the enzyme topoisomerase II is critical for proper cell
functioning. As such, compounds which inhibit the activity of topoisomerase II have
been used as anticancer agents in chemotherapeutic regimens. The previously discussed
research also indicates that caffeine inhibits the effect of several anticancer drugs, while
other compounds have their effects intensified. To determine the consequences of the
addition of caffeine on the ability of ten anticancer drugs to affect the activity of
topoisomerase II, topoisomerase II inhibition assays were performed.
One of the essential cellular functions of topoisomerase II is the separation of
supercoiled DNA strands via the formation of a double-strand break through which a
section of double-stranded DNA may be passed [McDowall, 2014]. This mechanism can
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be used to lower the degree of supercoiling of circular DNA [Klenin and Langowski,
2000]. Therefore, a method for monitoring the catalytic activity of the topoisomerase II
enzyme is to observe the stepwise relaxation of a supercoiled plasmid to its relaxed form
[Affymetrix, 2009].
The topoisomerase II assay method employed in this thesis is based upon previous
work by Ping Zhang at the University of Alabama in Huntsville, Huntsville, AL [Zhang,
1995], and utilizes the relaxation of supercoiled DNA by topoisomerase II as an indicator
of enzyme activity.
2.2.1 pBR322 Plasmid DNA as Substrate of Enzyme
pBR322 plasmid DNA was used as the substrate of topoisomerase II in the
relaxation reaction. pBR322 is a double-stranded, closed circular, medium copy plasmid
measuring 4361 base pairs long and weighing 2.83  106 Da. The purchased preparation
was over 90% comprised of molecules in the supercoiled form [Thermo Scientific, 2012].
2.2.2 Definition of Enzyme Activity
Recombinant human topoisomerase IIα was expressed in E. coli and packaged
with over 98% purity. One unit of enzyme was defined as the amount of enzyme which
can fully relax 0.3 µg of negatively supercoiled pBR322 plasmid DNA in 15 minutes at
30oC, utilizing a 10X reaction buffer of 100 mM Tris-HCl, pH 7.9, 500 mM NaCl, 500
mM KCl, 50 mM MgCl2, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.15 mg/mL
bovine serum albumin (BSA), and 10 mM ATP [Affymetrix, 2014].
Under the given reaction conditions, the double-stranded DNA passage
mechanism will relax supercoiled pBR322 plasmid DNA. This produces a selection of
plasmids which are chemically identical, yet vary in their degree of supercoiling from

38

fully supercoiled down to “linear” (fully relaxed / circular) DNA. Because
approximately fifteen independent strand passage events are required to fully relax the
pBR322 plasmid [Zhang, 1995], topoisomers exhibiting various degrees of superhelicity
are visible following treatment with topoisomerase II.
The products of these stepwise unwinding events are visible as discrete bands
during agarose gel electrophoresis (Figure 2.1, lane 3). When placed in an electrical
current, DNA fragments migrate through the agarose gel towards the positively charged
anode in a manner typically dependent on size, where smaller molecules are able to pass
through the gel more quickly. However, due to their compact topology, supercoiled
plasmids are able to move through the agarose gel more quickly than their linear
counterparts of identical size. As such, the distinct topoisomers of pBR322 DNA
resulting from different quantities of strand passage events can be separated based on
their individual migration rates through the agarose gel.
2.2.3 Etoposide as a Positive Control for Establishing a Threshold for Inhibition
in the Topoisomerase II Assay
As mentioned in chapter 1, etoposide is a known topoisomerase II inhibitor
currently in use as an anticancer drug. Therefore, it was chosen in this study as a positive
control for enzyme inhibition in the topoisomerase II inhibition assay. 25 µM–100 µM
etoposide was added to the standard topoisomerase II assay to examine variations in the
appearance of pBR322 plasmid DNA banding patterns as a result of topoisomerase
inhibition (Figure 2.1).
Theoretically, complete inhibition of the topoisomerase enzyme would result in a
lack of any banding patterns visible “above” the supercoiled band. However, for
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purposes of establishing a “minimum inhibitory concentration” of various anticancer
drugs in subsequent experiments, it was determined that presence of a supercoiled band
with double the volume (intensity) of the supercoiled band in a simultaneously-run lane
with uninhibited topoisomerase II was indicative of sufficient topoisomerase II inhibition
to select a concentration for further testing (Table 2.1). Similarly, the moderate presence
of a banding pattern above the supercoiled band was taken into consideration when
selecting a minimum inhibitory concentration. This degree of partial inhibition was
chosen to allow for the ability to view the effects of both inhibition and potentiation of
the drugs during subsequent testing.
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Figure 2.1. Inhibition by etoposide as a positive control. Left: gel image prior to
densitometry analysis. Right: gel image following densitometry analysis. Bands
surrounded by pink boxes indicate the supercoiled band in each lane, while the yellow
dot within the box marks the center of the band for apparent molecular weight
determination. 1: λ DNA HindIII digest markers; 2: 0.3 µg pBR322 DNA without
enzyme; 3: DNA with 2 units of topoisomerase II enzyme; 4: DNA, enzyme, and 25 µM
etoposide; 5: DNA, enzyme, and 50 µM etoposide; 6: DNA, enzyme, and 100 µM
etoposide.
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Table 2.1: Comparison of Band Intensity Levels of Supercoiled DNA in Inhibition
Control Gel with Etoposide. “Percent of enzyme control” calculated by dividing the
volume (intensity) of each supercoiled band by the intensity of the supercoiled band in
the associated lane with uninhibited topoisomerase II (Lane 3).

Lane

Volume (Intensity)

Percent of enzyme control

2

64,221,473

301%

3

21,333,056

100%

4

31,464,767

147%

5

50,157,148

235%

6

52,515,123

246%

Assays containing more intense supercoiled bands and a decrease in slowerrunning bands produced by the unwinding of plasmid DNA were observed as a result of
the addition of known topoisomerase II inhibitor etoposide. The supercoiled band of the
DNA-only control lane (Lane 2) was three times as intense as the supercoiled band of the
lane with uninhibited active topoisomerase (Lane 3). Lanes 5 (50 µM etoposide) and 6
(100 µM etoposide) were chosen as positive control examples for enzyme inhibition,
showing significantly more intense supercoiled bands and a reduction in the number of
visible bands. These lanes show supercoiled bands greater than two times the intensity of
the supercoiled band seen in the functional topoisomerase II reaction in lane 3. It was
therefore determined that a threshold of a supercoiled band with double the intensity of
an uninhibited reaction would serve as a suitable indicator of topoisomerase inhibition.
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2.2.4 Standard Topoisomerase II Assay Protocol
Prior to assay, pBR322 was diluted to a concentration of 0.15 µg/µL in 10mM
Tris-HCl, pH 7.6, and 1 mM EDTA. Topoisomerase II was diluted to a concentration of
2 units/µL in 10 mM sodium phosphate, pH 7.1, 50 mM NaCl, 0.2 mM DTT, 0.1 mM
EDTA, 0.5 mg/mL BSA, and 10% glycerol.
Standard topoisomerase II inhibition assay components included 0.3 µg of
pBR322 plasmid DNA, 1 mM ATP, two units of topoisomerase II, 2 µL of 10X
topoisomerase II reaction buffer (100 mM Tris-HCl, pH 7.9, 500 mM NaCl, 500 mM
KCl, 50 mM MgCl2, 1 mM EDTA, 0.15 mg/mL BSA, and 10 mM ATP), and sterile
water to bring the total volume to 20 µL. Anticancer drugs and caffeine were added as
needed. Samples were incubated at 36oC for 30 minutes, and then relaxation was stopped
by the addition of 3 µL of 7 mM EDTA, 0.77% SDS, 60% sucrose, and 0.05%
bromphenol blue. Assay mixtures were heated to 70oC for two minutes, and then loaded
into individual wells of a 1% agarose gel. Electrophoresis proceeded in 1X TBE buffer
(90 mM Tris-borate, pH 8.2, 2 mM EDTA). Large gels (20 cm  25 cm) were run at 60
V for 7-8 hours, and voltage was lowered to 10 V and allowed to run overnight. Smaller
gels (7 cm  9.5 cm) were run at 60 V for approximately 4 hours. Gels were stained for
30 minutes in aqueous 1 µg/mL ethidium bromide, and then placed in a water rinse
briefly to destain. DNA bands were visualized by transillumination with ultraviolet light
(approximately 300 nm, maximum intensity) using the Kodak EDAS 290 Gel Imager and
photographed using Kodak 1D image analysis software at a 6 second exposure time.
Analysis of gels was performed using MYImage Analysis software.
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2.3 Densitometry Analysis
Densitometry analysis for the gels was performed using MYImageAnalysis
software. Selection of supercoiled bands was performed manually. Volume (intensity)
of each band was determined by the software as the sum of each pixel’s grayscale
intensity, multiplied by the number of pixels in the band region.
Where relevant, the bands produced by various degrees of supercoiling among
plasmids, relative to the migration rate of the lambda DNA HinDIII digest ladder, were
evaluated and assigned “sizes” through linear (semi-log) regression analysis by the
MYImageAnalysis software. It should be noted, however, that these size designations
represent only the relative migration rate of the bands, and that all DNA bands visible
following the assay consist of 4361-base-pair-long continuous DNA molecules. In
instances where the entire pattern of banding appears shifted towards the negative
cathode, the apparent increase in weight is thought to be due not to an increase in base
pair number, but to an increase in molecular weight due to intercalated anticancer drugs.
2.4 Experimental Overview
Following the establishment of enzyme and positive inhibition controls, the effect
of the chosen anticancer drugs, varying by orders of magnitude, on the DNA substrate in
the absence of enzyme was observed as a control. Then, the effect of the anticancer
drugs on the activity of topoisomerase II was determined, and minimum inhibitory
concentrations were established. The chosen concentrations were tested for how they
were affected by caffeine in the absence of enzyme, and then the effect of caffeine on the
ability of the drugs to inhibit topoisomerase II was determined. Finally, combinations of
the minimum inhibitory concentrations of anticancer agents were tested in pairs without

44

topoisomerase II and in the presence of the enzyme. Finally, the effects of caffeine on
selected combinations of drugs were determined. Figure 2.2 shows a flow chart of the
experimental design.

Topoisomerase II
Establish active concentration
of enzyme.

Anticancer Agents with
Topoisomerase II
Find minimum concentration at
which topoisomerase II activity is
inhibited.

Anticancer Agents with Caffeine

Anticancer Agents in Combination

Find concentration of caffeine at
which topoisomerase II activity is
either restored or further inhibited.

Examine the effects of drugs in
combination to see if they enhance
or inhibit one another.

Combinations of Anticancer
Agents and Caffeine
How does the presence of multiple
drugs and caffeine affect the
activity of topoisomerase II?

Figure 2.2. Flow chart of experimental design.
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CHAPTER THREE

RESULTS

Fluorescent bands on the agarose gels were identified according to their relative
positions, as shown by Figure 3.1.

Figure 3.1. Cartoon representation of relative migration rates of bands in a
topoisomerase II assay. Based on info from [Tirabassi, 2014].
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The visible results of the activity levels of two to four units of topoisomerase II
(TopoII) were compared to confirm the use of two units of enzyme for further testing
(Figure 3.2). Potential effects of the anticancer agents (Table 3.1) on the pBR322 DNA
itself were examined as a control (Figures 3.2-3.4). Contents of each lane of the gels are
given in the accompanying tables (Tables 3.2, 3.4, and 3.6). Tables 3.3, 3.5, and 3.7 give
the volume (in intensity) and apparent size of any visible supercoiled bands to observe
intercalation.

Table 3.1: Maximum Concentration Tested of Each Anticancer Agent. Ten-fold
dilutions into water were prepared for each drug until the minimum inhibitory
concentration was established.

Drug
Berberine
Chelerythrine
Doxorubicin
Sanguinarine
Tingenone
Paclitaxel
Malvidin
Delphinidin
Ellipticine
Pelargonidin

% (w/v)
0.1%
1%
1%
1%
1%
0.1%
0.1%
1%
1%
1%

Molarity
2.689 mM
26.05 mM
17.24 mM
27.19 mM
23.78 mM
1.171 mM
3.018 mM
32.98 mM
40.60 mM
32.61 mM
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% DMSO in solvent
10%
100%
100%
100%
100%
100%
100%
100%
100%
100%

Figure 3.2. Topoisomerase II assay of various topoisomerase II concentrations and
anticancer agents without enzyme. Lane contents shown in Table 3.2.

Table 3.2: Lane Contents of Topoisomerase II Assay of Various Topoisomerase II
Concentrations and Anticancer Agents without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
3 units
4 units
-

ATP
1mM
1mM
1mM
-

Anticancer agent
λ DNA HindIII digest
10-1% Berberine (1µL)
10-2% Berberine (1µL)
10-3% Berberine (1µL)
10-4% Berberine (1µL)
1% Chelerythrine (1µL )
10-1% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-3% Chelerythrine (1µL)
10-4% Chelerythrine (1µL)
1% Doxorubicin (1µL)
10-1% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-3% Doxorubicin (1µL)
10-4% Doxorubicin (1µL)
1% Sanguinarine (1µL)
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10X Buffer
2 µL
2 µL
2 µL
-

Table 3.3: Volume and Apparent Size of Supercoiled Bands in Figure 3.2.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
36,570,329
29,204,452
18,822,680
17,731,201
33,411,285
38,280,664
29,875,479
30,772,923
37,207,689
28,452,213

Apparent
size (bp)
3,235.82
3,578.85
3,416.29
3,420.09
3,372.22
3,364.64
3,373.19
3,383.65
3,598.61**
3,564.70**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
25,721,588
28,527,514
20,582,873
none
none
none
30,648,792
25,476,924
32,272,261
-

Apparent
size (bp)
3,575.87**
3,642.01**
3,754.96**
none
none**
none**
3,905.04**
3,334.90
3,686.41**
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.3. Topoisomerase II assay of anticancer agents without enzyme. Lane contents
shown in Table 3.4.
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Table 3.4: Lane Contents of Topoisomerase II Assay of Anticancer Agents without
Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
-

ATP
-

Anticancer agent
λ DNA HindIII digest
10-1% Sanguinarine (1µL)
10-2% Sanguinarine (1µL)
10-3% Sanguinarine (1µL)
10-4% Sanguinarine (1µL)
1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Tingenone (1µL)
10-3% Tingenone (1µL)
10-4% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Paclitaxel (1µL)
10-3% Paclitaxel (1µL)
10-4% Paclitaxel (1µL)
10-5% Paclitaxel (1µL)
10-1% Malvidin (1µL)
10-2% Malvidin (1µL)
10-3% Malvidin (1µL)
10-4% Malvidin (1µL)
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10X Buffer
-

Table 3.5: Volume and Apparent Size of Supercoiled Bands in Figure 3.3.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
31,742,841
35,084,355
42,996,100
33,655,949
36,591,403
37,315,115
35,421,539
34,995,690
35,049,917
33,646,183

Apparent
size (bp)
3,213.60
3,494.30
3,484.63**
3,239.89
3,212.52
3,221.44
3,204.70
3,196.36
3,166.71
3,162.46

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
35,166,338
32,211,866
32,133,738
33,227,530
31,302,600
29,107,820
26,442,730
23,463,586
21,214,579
-

Apparent
size (bp)
3,177.63
3,150.78
3,146.03
3,101.96
3,075.49
3,086.61
3,023.74
2,952.97
2,902.31
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.4. Topoisomerase II assay of anticancer agents without enzyme and DMSO
controls without enzyme. Lane contents shown in Table 3.6.
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Table 3.6: Lane Contents of Topoisomerase II Assay of Anticancer Agents without
Enzyme and DMSO Controls without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
-

ATP
1 mM
-

Anticancer agent
λ DNA HindIII digest
1% Delphinidin (1µL)
10-1% Delphinidin (1µL)
10-2% Delphinidin (1µL)
10-3% Delphinidin (1µL)
10-4% Delphinidin (1µL)
1% Ellipticine (1µL)
10-1% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-3% Ellipticine (1µL)
10-4% Ellipticine (1µL)
1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Pelargonidin (1µL)
10-3% Pelargonidin (1µL)
10-4% Pelargonidin (1µL)
100% DMSO (1µL)
10% DMSO (1µL)

52

10X Buffer
2 µL
-

Table 3.7: Volume and Apparent Size of Supercoiled Bands in Figure 3.4.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
30,744,653
37,760,496
none
34,425,921
32,970,016
31,706,347
37,479,081
52,017,314
57,215,139
56,364,469

Apparent
size (bp)
3,316.78
3,416.46
none
3,519.26
3,508.85
3,540.12
3,646.60
4,540.53**
4,553.93**
4,473.79**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
32,432,115
33,019,103
23,604,679
60,732,184
46,943,620
50,747,477
34,383,516
29,670,136
23,605,707
-

Apparent
size (bp)
3,926.99**
3,812.25
3,277.70
4,377.09
5,096.73
4,621.93
3,926.91
3,834.84
3,756.29
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Anticancer agents were tested in ten-fold dilutions of their maximum available
concentration until the minimum concentrations capable of showing visible
topoisomerase II inhibition were discovered (Figures 3.5–3.9). Selection of minimum
inhibitory concentrations was determined by the volume of the supercoiled band as
determined through densitometry analysis and the presence of a banding pattern
indicative of unwound pBR322 plasmid DNA. Contents of each lane of the gels are
given in the accompanying tables (Tables 3.8, 3.10, 3.12, 3.14, and 3.17). Tables 3.9,
3.11, 3.13, 3.15, and 3.18 give the volume and apparent size of any visible supercoiled
bands.
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Figure 3.5. Topoisomerase II assay of anticancer agents doxorubicin, sanguinarine,
tingenone, and paclitaxel. Lane contents shown in Table 3.8.

Table 3.8: Lane Contents of Topoisomerase II Assay of Anticancer Agents Doxorubicin,
Sanguinarine, Tingenone, and Paclitaxel.
Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

ATP
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

Anticancer agent
λ DNA HindIII digest
1% Doxorubicin (1µL)
10-1% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-3% Doxorubicin (1µL)
10-4% Doxorubicin (1µL)
1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-2% Sanguinarine (1µL)
10-3% Sanguinarine (1µL)
10-4% Sanguinarine (1µL)
1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Tingenone (1µL)
10-3% Tingenone (1µL)
10-4% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Paclitaxel (1µL)
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10X Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.9: Volume and Apparent Size of Supercoiled Bands in Figure 3.5.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
38,648,945
none
none
20,847,583*
29,933,304*
none
none
76,498,620*
61,207,377*
60,494,459*

Apparent
size (bp)
2,906.21
none
none**
4,002.85**
4,163.63**
none**
none
3,742.18**
3,685.10**
5,243.35**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
none
none
32,279,200*
24,438,644*
none
none
none
15,385,048*
none
-

Apparent
size (bp)
none**
none
3,136.81
3,166.03
none
none
none
3,396.03
none
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.6. Topoisomerase II assay of anticancer agents paclitaxel, malvidin,
delphinidin, and ellipticine. Lane contents shown in Table 3.10.
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Table 3.10: Lane Contents of Topoisomerase II Assay of Anticancer Agents Paclitaxel,
Malvidin, Delphinidin, and Ellipticine.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

ATP
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

Anticancer agent
λ DNA HindIII digest
-3
10 % Paclitaxel (1µL)
10-4% Paclitaxel (1µL)
10-5% Paclitaxel (1µL)
10-1% Malvidin (1µL)
10-2% Malvidin (1µL)
10-3% Malvidin (1µL)
10-4% Malvidin (1µL)
10-5% Malvidin (1µL)
1% Delphinidin (1µL)
10-1% Delphinidin (1µL)
10-2% Delphinidin (1µL)
10-3% Delphinidin (1µL)
1% Ellipticine (1µL)
10-1% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-3% Ellipticine (1µL)
10-4% Ellipticine (1µL)
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10X Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.11: Volume and Apparent Size of Supercoiled Bands in Figure 3.6.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
37,381,421
none
none
none
none
33,822,742*
none
none
none
none

Apparent
size (bp)
2,934.09
none
none
none
none
3,014.16
none
none
none
none

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
45,234,570*
38,575,700*
37,447,984*
43,141,562*
61,869,409*
68,251,747*
26,293,413*
none
none
-

Apparent
size (bp)
2,987.28
3,960.51
2,960.46
2,969.35
3,545.56**
3,642.75**
3,675.60**
none
none
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

The effect of caffeine on the plasmid DNA was examined, as well as possible
inhibition of topoisomerase II activity by the addition of caffeine alone (1 µM–50 mM)
(Figures 3.7–3.8). Also, possible inhibitory effects of DMSO were examined in the
concentrations used as solvents for the anticancer agents (0.01%–100%) (Figure 3.8).
Contents of each lane of the gels are given in the accompanying tables (Tables 3.12 and
3.14). Tables 3.13 and 3.15 give the volume and apparent size of any visible supercoiled
bands.
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Figure 3.7. Topoisomerase II assay of anticancer agent pelargonidin and caffeine
controls. Lane contents shown in Table 3.12.

Table 3.12. Lane Contents of Topoisomerase II Assay of Anticancer Agent Pelargonidin
and Caffeine Controls.
Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

ATP
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

Anticancer agent
λ DNA HindIII digest
1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Pelargonidin (1µL)
10-3% Pelargonidin (1µL)
10-4% Pelargonidin (1µL)
1000 uM etoposide (2µL)
-
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[Caffeine]
50 mM
10 mM
1 mM
100 µM
10 µM
1 µM
50 mM
10 mM
1 mM
100 µM
10 µM

10X Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.13: Volume and Apparent Size of Supercoiled Bands in Figure 3.7.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
33,882,880
13,245,009
33,592,213*
33,205,942*
14,285,859
16,818,851
none
35,233,672*
36,270,667*
38,285,033*

Apparent
size (bp)
3,208.09
3,342.16
3,269.27
3,310.70
3,503.74
3,514.92
none
3,438.18
3,481.75
3,503.74

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
42,283,696*
82,722,903*
44,896,358*
74,246,015*
27,021,494*
16,275,810
10,907,851
9,949,498
6,647,819
-

Apparent
size (bp)
3,559.33
4,075.77
4,521.54
4,205.68
3,594.31
3,616.27
3,696.37
3,593.10
3,559.33
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.8. Topoisomerase II assay of final caffeine control, DMSO controls, and
anticancer agents berberine, chelerythrine, and delphinidin. Lane contents shown in
Table 3.14.
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Table 3.14: Lane Contents of Topoisomerase II Assay of Final Caffeine Control, DMSO
Controls and Anticacner Agents Berberine, Chelerythrine, and Delphinidin.

Lane pBR322
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII

ATP

Anticancer agent

[Caffeine]

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
%
100 DMSO (1µL)
10% DMSO (1µL)
1% DMSO (1µL)
0.1% DMSO (1µL)
0.01% DMSO (1µL)
10-1% Berberine (1µL)
10-2% Berberine (1µL)
10-3% Berberine (1µL)
10-4% Berberine (1µL)
1% Chelerythrine (1µL)
10-1% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-3% Chelerythrine (1µL)
10-4% Chelerythrine (1µL)
1% Delphinidin (1µL)
1% Delphinidin (1µL)

1 µM
-
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10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.15: Volume and Apparent Size of Supercoiled Bands in Figure 3.8.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
Apparent size
(Intensity)
(bp)
36,710,137
3,166.01
10,494,852
3,216.23
16,656,684
3,224.25
27,473,043*
3,205.13
12,708,136
3,247.76
5,698,204
3,247.26
9,479,445
3,287.89
10,237,595
3,298.78
30,473,261*
3,152.13
19,262,150
3,246.25

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
7,046,940
16,510,451
27,991,926*
33,628,193*
14,248,337
32,952,026*
9,659,859
none
16,435,407
-

Apparent
size (bp)
3,278.07
3,184.52
3,193.07
3,327.49**
3,368.76**
3,136.25
3,151.52
none
2,982.20
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Following the establishment of the minimum inhibitory concentration of each
anticancer agent (Table 3.16), the selected concentrations were tested in assays
containing equimolar and order-of-magnitude greater concentrations of caffeine, up to 50
mM. First, each anticancer agent and caffeine concentration was combined in the
absence of enzyme as a control (Figures 3.9-3.12). Contents of each lane of the gels are
given in the accompanying tables (Tables 3.17, 3.19, 3.21, and 3.23). Tables 3.18, 3.20,
3.22, and 3.24 give the volume and apparent size of any visible supercoiled bands.

61

Table 3.16: Minimum Inhibitory Concentrations of Anticancer Agents in Assay for Use
in Further Testing.

Drug

% (w/v)

Molarity

Berberine
Chelerythrine
Doxorubicin
Sanguinarine
Tingenone
Paclitaxel
Malvidin
Delphinidin
Ellipticine
Pelargonidin

0.01%
0.01%
0.01%
0.1%
0.1%
0.1%
0.1%
0.0001%
0.01%
0.1%

13.5 µM
13.1 µM
8.60 µM
136 µM
119 µM
58.5 µM
151 µM
165 nM
20.3 µM
163 µM

Dissolved
in %
DMSO
1%
1%
1%
10%
10%
100%
100%
0.01%
1%
10%

Figure 3.9. Topoisomerase II assay of duplicate berberine and chelerythrine, additional
dilutions of delphinidin, and doxorubicin and sanguinarine with caffeine but without
enzyme. Lane contents shown in Table 3.17.
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Table 3. 17: Lane Contents of Topoisomerase II Assay of Duplicate Berberine and
Chelerythrine, Additional Dilutions of Delphinidin, and Doxorubicin and Sanguinarine
with Caffeine but without Enzyme.

Lane pBR322 TopoII
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

ATP

Anticancer agent

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
-3
10 % Berberine (1µL)
10-4% Berberine (1µL)
10-2% Chelerythrine (1µL)
10-3% Chelerythrine (1µL)
10-4% Chelerythrine (1µL)
10-4% Delphinidin (1µL)
10-5% Delphinidin (1µL)
10-6% Delphinidin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
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[Caffeine]
in assay
0.0086 mM (1X)
0.086 mM (10X)
0.86 mM (100X)
8.6 mM (1000X)
50 mM (5814X)
0.136 mM (1X)
1.36 mM (10X)
13.6 mM (100X)
50 mM (368X)

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
-

Table 3.18: Volume and Apparent Size of Supercoiled Bands in Figure 3.9.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
35,580,622
15,527,426
10,266,636
13,757,724
24,433,761
13,526,424
none
17,809,072
15,316,429
11,010,137

Apparent
size (bp)
3,243.47
3,364.87
3,385.54
3,395.92
3,573.73
3,512.25
none
3,523.03
3,588.35
3,555.54

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
32,075,142*
28,460,437
27,519,817
26,603,098
29,235,292
58,239,541*
44,135,638*
48,122,993*
37,289,158*
-

Apparent
size (bp)
4,529.35**
4,594.60**
4,641.72**
4,655.95**
4,359.38**
4,047.70**
3,955.82**
3,943.73**
3,848.30**
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.10. Topoisomerase II assay of tingenone, paclitaxel, malvidin, and ellipticine
with caffeine, without enzyme. Lane contents shown in Table 3.19.
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Table 3.19: Lane Contents of Topoisomerase II Assay of Tingenone, Paclitaxel,
Malvidin, and Ellipticine with Caffeine, Without Enzyme.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
-

1 mM
-

λ DNA HindIII digest
10-1% Tingenone (1 µL)
10-1% Tingenone (1 µL)
10-1% Tingenone (1 µL)
10-1% Tingenone (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Malvidin (1 µL)
10-1% Malvidin (1 µL)
10-1% Malvidin (1 µL)
10-1% Malvidin (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
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[Caffeine]
in assay
0.119 mM (1X)
1.19 mM (10X)
11.9 mM (100X)
50 mM (421X)
0.0586 mM (1X)
0.586 mM (10X)
5.86 mM (100X)
50 mM (854X)
0.151 mM (1X)
1.51 mM (10X)
15.1 mM (100X)
50 mM (331X)
0.0203 mM (1X)
0.203 mM (10X)
2.03 mM (100X)
20.3 mM (.1000X)
50 mM (2463X)

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
-

Table 3.20: Volume and Apparent Size of Supercoiled Bands in Figure 3.10.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
29,355,311
11,330,102
38,203,307*
37,426,653*
40,602,402*
39,675,146*
38,224,124*
39,425,085*
41,285,251*
35,009,311*

Apparent
size (bp)
3,121.15
3,153.46
3,119.64
3,113.61
3,130.62
3,116.98
3,086.54
3,095.90
3,111.71
3,085.04

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
37,213,857*
40,950,380*
40,152,909*
32,929,410*
53,208,252*
49,414,161*
56,249,590*
40,032,890*
26,480,509*
-

Apparent
size (bp)
3,097.79
3,063.83
3,057.87
3,056.39
3,485.92**
3,466.94**
3,453.94**
3,129.86**
3,014.09
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.11. Topoisomerase II assay of berberine, chelerythrine, and delphinidin with
caffeine, without enzyme. Lane contents shown in Table 3.21.
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Table 3.21: Lane Contents of Topoisomerase II Assay of Berberine, Chelerythrine, and
Delphinidin with Caffeine, without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322 TopoII

ATP

Anticancer agent

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

1 mM
-

λ DNA HindIII digest
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)

2 units
-
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[Caffeine]
in assay
0.0135 mM (1X)
0.135 mM (10X)
1.35 mM (100X)
13.5 mM (1000X)
50 mM (3719X)
0.0130 (1X)
0.130 (10X)
1.30 (100X)
13.0 mM (1000X)
50 mM (3839X)
0.165 µM (1X)
1.65 µM (10X)
16.5 µM (100X)
0.165 mM (1000X)
1.65 mM (10,000X)
16.5 mM (100,000X)
50 mM (303,951X)

10X
Buffer
2 µL
-

Table 3.22: Volume and Apparent Size of Supercoiled Bands in Figure 3.11.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
34,469,868
33,734,591
35,898,531
36,015,466
36,171,722
36,277,092
34,894,689
33,534,131
33,910,122
32,721,754

Apparent
size (bp)
3,163.03
3,181.01
3,199.03
3,217.26
3,235.56
3,253.96
3,253.94
3,344.99**
3,345.80**
3,335.56**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
30,749,279
33,778,281
35,164,282
31,051,768
34,302,304
34,389,427
33,137,066
30,039,959
24,077,816
-

Apparent
size (bp)
3,308.15**
3,299.60**
3,235.54
3,215.34
3,199.10
3,181.02
3,092.07
3,028.76
2,971.70
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Next, each anticancer agent and caffeine concentration were combined in the
presence of topoisomerase to observe the effect of caffeine on the drug’s ability to affect
the enzyme (Figures 3.12–3.14). Contents of each lane of the gels are given in the
accompanying tables (Tables 3.23, 3.25, and 3.27). Tables 3.24, 3.26, and 3.28 give the
volume and apparent size of any visible supercoiled bands.
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Figure 3.12. Topoisomerase II assay of pelargonidin with caffeine without enzyme, and
paclitaxel, malvidin, and ellipticine with caffeine and enzyme. Lane contents shown in
Table 3.23.
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Table 3.23: Lane Contents of Topoisomerase II Assay of Pelargonidin with Caffeine
without Enzyme, and Paclitaxel, Malvidin, and Ellipticine with Caffeine and Enzyme.

Lane pBR322 TopoII
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

ATP

Anticancer agent

2 units

1 mM

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
10-1% Pelargonidin (1 µL)
10-1% Pelargonidin (1 µL)
10-1% Pelargonidin (1 µL)
10-1% Pelargonidin (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Paclitaxel (1 µL)
10-1% Malvidin (1 µL)
10-1% Malvidin (1 µL)
10-1% Malvidin (1 µL)
10-1% Malvidin (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
10-2% Ellipticine (1 µL)
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[Caffeine]
10X
in assay
Buffer
2 µL
0.163 mM (1X)
1.63 mM (10X)
16.3 mM (100X)
50 mM (307X)
0.0586 mM (1X)
2 µL
0.586 mM (10X)
2 µL
5.86 mM (100X)
2 µL
50 mM (854X)
2 µL
0.151 mM (1X)
2 µL
1.51 mM (10X)
2 µL
15.1 mM (100X)
2 µL
50 mM (331X)
2 µL
0.0203 mM (1X)
2 µL
0.203 mM (10X)
2 µL
2.03 mM (100X)
2 µL
20.3 mM (1000X) 2 µL
50 mM (2463X)
2 µL

Table 3.24: Volume and Apparent Size of Supercoiled Bands in Figure 3.12.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
29,541,122
28,926,121
35,058,912
33,836,363
31,756,976
32,535,943
31,775,737
30,559,870
33,719,171
30,696,851

Apparent
size (bp)
3,138.23
3,143.20
3,192.95
3,198.94
3,187.17
3,189.07
3,217.68
3,225.37
3,246.55
3,235.67

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
32,594,539
29,018,641
30,354,013
32,591,712
50,633,883
50,480,968
50,842,310
36,929,358
28,338,105
-

Apparent
size (bp)
3,204.92
3,175.77
3,192.15
3,180.81
3,788.57**
3,808.90**
3,765.26**
3,572.40**
3,343.99
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.13. Topoisomerase II assay of anticancer agents berberine, chelerythrine, and
delphinidin with caffeine and enzyme. Lane contents shown in Table 3.25.
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Table 3.25: Lane Contents of Topoisomerase II Assay of Anticancer Agents Berberine,
Chelerythrine, and Delphindin with Caffeine and Enzyme.

Lane pBR322 TopoII
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

ATP

Anticancer agent

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Berberine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-2% Chelerythrine (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
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[Caffeine]
in assay
0.0135 mM (1X)
0.135 mM (10X)
1.35 mM (100X)
13.5 mM (1000X)
50 mM (3719X)
0.0130 (1X)
0.130 (10X)
1.30 (100X)
13.0 mM (1000X)
50 mM (3839X)
0.165 µM (1X)
1.65 µM (10X)
16.5 µM (100X)
0.165 mM (1000X)
1.65 mM (10,000X)
16.5 mM (100,000X)
50 mM (303,951X)

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.26: Volume and Apparent Size of Supercoiled Bands in Figure 3.13.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
29,727,704
29,796,066
25,839,551
26,951,847
27,169,269
23,423,751
26,665,035
17,936,801
23,394,967
17,924,722

Apparent
size (bp)
3,170.87
3,215.43
3,233.02
3,289.76
3,308.11
3,345.12
3,458.18**
3,644.67**
3,669.80**
3,659.82**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
24,526,024
32,413,354
37,893,879
38,701,630
44,596,439
28,128,650
28,008,888
2,580,299
21,220,747
-

Apparent
size (bp)
3,687.56**
3,831.23**
3,989.53**
3,988.54**
3,933.70**
3,471.72
3,423.58
3,365.72
3,308.50
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.14. Topoisomerase II assay of anticancer agents pelargonidin, doxorubicin,
sanguinarine, and tingenone with caffeine and enzyme. Lane contents shown in Table
3.27.
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Table 3.27: Lane Contents of Topoisomerase II Assay of Anticancer Agents
Pelargonidin, Doxorubicin, Sanguinarine, and Tingenone with Caffeine and Enzyme.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
10-1% Pelargonidin (1 µL)
10-1% Pelargonidin (1 µL)
10-1% Pelargonidin (1 µL)
10-1% Pelargonidin (1 µL)
10-2% Doxorubicin (1 µL)
10-2% Doxorubicin (1 µL)
10-2% Doxorubicin (1 µL)
10-2% Doxorubicin (1 µL)
10-2% Doxorubicin (1 µL)
10-1% Sanguinarine (1 µL)
10-1% Sanguinarine (1 µL)
10-1% Sanguinarine (1 µL)
10-1% Sanguinarine (1 µL)
10-1% Tingenone (1 µL)
10-1% Tingenone (1 µL)
10-1% Tingenone (1 µL)
10-1% Tingenone (1 µL)
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[Caffeine]
in assay
0.163 mM (1X)
1.63 mM (10X)
16.3 mM (100X)
50 mM (307 X)
0.0086 mM (1X)
0.086 mM (10X)
0.86 mM (100X)
8.6 mM (1000X)
50 mM (5814X)
0.136 mM (1X)
1.36 mM (10X)
13.6 mM (100X)
50 mM (368X)
0.119 mM (1X)
1.19 mM (10X)
11.9 mM (100X)
50 mM (421X)

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.28: Volume and Apparent Size of Supercoiled Bands in Figure 3.14.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
30,944,342
30,029,422
30,524,918
35,442,099
38,059,130
37,223,623
none
none
none
none

Apparent
size (bp)
3,201.64
3,233.33
3,231.05
3,207.41
3,240.67
3,247.64
none**
none**
none**
none**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
27,431,152
40,753,518
38,242,114
36,998,234
42,296,803
32,552,648
26,089,355
24,725,199
18,508,369
-

Apparent
size (bp)
3,787.45**
3,683.35**
3,697.18**
3,643.41**
3,586.76**
3,168.41
3,132.47
3,089.92
3,062.03
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Minimum inhibitory concentrations of selected anticancer agents (berberine,
chelerythrine, doxorubicin, sanguinarine, tingenone, paclitaxel, delphinidin, ellipticine,
and pelargonidin) were combined in the absence of enzyme as a control (Figures 3.15 and
3.16), and in the presence of topoisomerase II (Figures 3.17 and 3.18). Contents of each
lane of the gels are given in the accompanying tables (Tables 3.29, 3.31, 3.33, and 3.35).
Tables 3.30, 3.32, 3.34, and 3.36 give the volume and apparent size of any visible
supercoiled bands.
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Figure 3.15. First topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations, without enzyme. Lane contents shown in Table
3.29. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone
(T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 3.29: Lane Contents of First Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations, without Enzyme.

Lane

pBR322

TopoII

ATP

Anticancer agent #1

Anticancer agent #2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

-

-

λ DNA HindIII digest
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)

10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
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10X
Buffer

-

Table 3.30: Volume and Apparent Size of Supercoiled Bands in Figure 3.15.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
34,450,336
none
none
53,025,268
43,174,458
41,212,263
54,442,366
43,890,460
none
none

Apparent
size (bp)
3,261.05
none
none**
3,754.12**
3,527.20
3,548.11
3,938.10**
3,628.87
none**
none**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
none
none
none
none
44,852,411
51,509,996
51,251,454
48,530,595
34,546,711
-

Apparent
size (bp)
none**
none**
none**
none**
4,386.32**
4,268.51**
4,216.62**
4,265.86**
4,085.56**
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.16. Second topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations, without enzyme. Lane contents shown in Table
3.31. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone
(T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 3.31: Lane Contents of Second Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations, without Enzyme.

Lane

pBR322

TopoII

ATP

Anticancer agent #1

Anticancer agent #2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

-

-

λ DNA HindIII digest
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)

10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
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10X
Buffer

-

Table 3.32: Volume and Apparent Size of Supercoiled Bands in Figure 3.16.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
29,980,592
none
30,200,584
29,953,093
30,946,141
30,465,808
32,307,213
36,436,175
30,787,572
31,657,517

Apparent
size (bp)
3,191.56
none
3,157.03
3,157.05
3,595.27**
3,174.69
3,175.46
3,565.32**
3,177.20
3,538.55**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
32,375,575
34,105,185
29,677,846
7,510,825
29,472,246
23,901,771
22,619,598
36,736,608
28,218,086
-

Apparent
size (bp)
3,156.65
3,618.86**
3,223.51
3,922.28**
3,391.21**
3,007.90
2,994.13
3,387.73**
2,909.42
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.17. First topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations with enzyme. Lane contents shown in Table 3.33.
Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone (T),
Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 3.33: Lane Contents of First Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations with Enzyme.

Lane

pBR322

TopoII

ATP

Anticancer agent #1

Anticancer agent #2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)

10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
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10X
Buffer

2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.34: Volume and Apparent Size of Supercoiled Bands in Figure 3.17.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
38,365,474
none
37,025,990*
none
none
none
42,699,265*
none
27,281,064*
29,306,481*

Apparent
size (bp)
3,159.33
none
4,158.99**
none
none
none
4,054.14**
none
4,135.76**
4,145.69**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
35,201,804*
31,844,870*
34,297,678*
30,835,888*
none
none
none
none
none
-

Apparent
size (bp)
4,168.92**
4,155.63**
4,137.42**
4,124.29**
none
none
none
none
none
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.18. Second topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations with enzyme. Lane contents shown in Table 3.35.
Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone (T),
Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 3.35: Lane Contents of Second Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations with Enzyme.

Lane

pBR322

TopoII

ATP

Anticancer agent #1

Anticancer agent #2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

λ DNA HindIII digest
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)

10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
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10X
Buffer

2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Table 3.36: Volume and Apparent Size of Supercoiled Bands in Figure 3.18.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
28,901,449
none
none
none
none
none
none
none
none
19,477,516*

Apparent
size (bp)
3,113.96
none
none
none
none**
none
none
none**
none
4,305.53**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
none
18,243,402*
none
22,299,890*
none
none
none
25,789,950*
none
-

Apparent
size (bp)
none
3,817.47**
none
4,070.78**
none
none
none
4,068.10**
none
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Finally, five anticancer agents were selected for further study in combination at
their minimum inhibitory concentrations with caffeine. The drugs selected, based upon
previous results in combination and individually with caffeine, were ellipticine,
berberine, delphinidin, doxorubicin, and tingenone. The selected concentrations of
caffeine were those deemed significant from previous testings, up to 50 mM.
Concentrations of caffeine given are multiples of the total drug concentration in the
assay. Figures 3.19 and 3.20 show assays containing multiple drugs and caffeine
combined in the absence of enzyme as a control. Figures 3.21 and 3.22 combine multiple
anticancer agents and caffeine in the presence of topoisomerase II. Contents of each lane
of the gels are given in the accompanying tables (Tables 3.37, 3.39, 3.41, and 3.43).
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Tables 3.38, 3.40, 3.42, and 3.44 give the volume and apparent size of any visible
supercoiled bands.
Figure 3.19 also shows verification of previous results of berberine tested with
caffeine.

Figure 3.19. Topoisomerase II assay of berberine with caffeine and enzyme, and selected
anticancer agents in combination with caffeine without enzyme. Lane contents shown in
Table 3.37. Berberine (B), Delphinidin (De).
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Table 3.37: Lane Contents of Topoisomerase II Assay of Berberine with Caffeine and
Enzyme, and Selected Anticancer Agents in Combination, with Caffeine, without
Enzyme. 10X buffer (not shown) added to lanes containing topoisomerase.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
2 units
2 units
2 units
2 units
-

1st Anticancer agent
λ DNA HindIII digest
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)
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2nd Anticancer agent
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-4% Delphinidin (1 µL)

[Caffeine]
0.135 mM (10X)
1.35 mM (100X)
13.5 mM (1000X)
50 mM (3719X)
0.338 mM (10X)
3.38 mM (100X)
33.8 mM (1000X)
50 mM (1481X)
0.205 mM (10X)
2.05 mM (100X)
20.5 mM (1000X)
50 mM (2444X)
28.9 mM (100X)
50 mM (1730X)
13.9 mM (100X)
50 mM (359X)
0.136 mM (10X)

Table 3.38: Volume and Apparent Size of Supercoiled Bands in Figure 3.19.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
32,788,317
20,648,665
24,565,859
29,311,364
23,097,361
29,412,879
40,033,661
43,221,232*
32,919,130
34,956,112

Apparent
size (bp)
3,098.20
3,223.68
3,255.84
3,321.12
3,322.50
3,365.39
3,995.51**
4,008.75**
3,656.32**
3,660.10**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
60,496,001*
73,154,536*
47,166,953
40,140,316
none
none
30,164,347
29,662,940
28,699,961
-

Apparent
size (bp)
4,175.42**
4,259.14**
3,871.86**
3,804.41**
none**
none**
3,929.14**
3,799.69**
3,600.05
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.20. Topoisomerase II assay of selected anticancer agents in combination, with
caffeine, without enzyme. Lane contents shown in Table 3.39.
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Table 3.39: Lane Contents of Topoisomerase II Assay of Selected Anticancer Agents in
Combination, with Caffeine, Without Enzyme. 10X buffer (not shown) added to lanes
containing topoisomerase.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
-

1st Anticancer agent
λ DNA HindIII digest
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
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2nd Anticancer agent
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)

[Caffeine]
1.36 mM (100X)
13.6 mM (1000X)
50 mM (3676X)
0.22 mM (10X)
2.2 mM (100X)
22 mM (1000X)
50 mM (2273X)
0.132 mM (1X)
1.32 mM (10X)
13.2 mM (100X)
50 mM (379X)
0.0877 mM (10X)
0.877 mM (100X)
8.77 mM (1000X)
50 mM (5705X)
12.8 mM (100X)
50 mM (392X)

Table 3.40: Volume and Apparent Size of Supercoiled Bands in Figure 3.20.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
29,379,726
15,652,328
31,088,005*
32,976,441*
31,558,058*
none
none
none
none
33,537,472*

Apparent
size (bp)
3,029.05
3,099.24
3,079.02
3,089.12
3,099.24
none**
none**
none**
none**
3,038.98

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
32,092,361*
34,684,977*
33,261,968*
none**
none**
none**
none**
none**
none**
-

Apparent
size (bp)
3,038.97
3,029.05
3,038.98
none**
none**
none**
none**
none**
none**
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.21. First topoisomerase II assay of selected anticancer agents in combination,
with caffeine and enzyme. Lane contents shown in Table 3.41. Berberine (B),
Delphinidin (De).
89

Table 3.41: Lane Contents of First Topoisomerase II Assay of Selected Anticancer
Agents in Combination, with Caffeine and Enzyme. 10X buffer (not shown) added to
lanes containing topoisomerase.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1st Anticancer agent
λ DNA HindIII digest
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)
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2nd Anticancer agent
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-4% Delphinidin (1 µL)

[Caffeine]
0.338 mM (10X)
3.38 mM (100X)
33.8 mM (1000X)
50 mM (1481X)
0.205 mM (10X)
2.05 mM (100X)
20.5 mM (1000X)
50 mM (2444X)
28.9 mM (1000X)
50 mM (1730X)
13.9 mM (100X)
50 mM (359X)
0.136 mM (10X)

Table 3.42: Volume and Apparent Size of Supercoiled Bands in Figure 3.21.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
24,877,343
15,766,693
none
none
none
none
34,510,731*
32,750,538*
24,552,495
24,094,407

Apparent
size (bp)
3,058.62
3,052.73
none
none
none
none
3,984.61**
3972.85**
3,595.11**
3,551.68**

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
37,230,819*
43,845,999*
33,600,437*
24,946,733
none
none
38,713,195*
24,271,080
10,929,953
-

Apparent
size (bp)
4,119.08**
4,200.25**
3,921.52**
3,659.93**
none**
none**
4,222.19**
3,549.50**
3,304.23
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.

Figure 3.22. Second topoisomerase II assay of selected anticancer agents in combination,
with caffeine and enzyme. Lane contents shown in Table 3.43.
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Table 3.43: Lane Contents of Second Topoisomerase II Assay of Selected Anticancer
Agents in Combination, with Caffeine and Enzyme. 10X buffer (not shown) added to
lanes containing topoisomerase.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

pBR322
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

TopoII
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1st Anticancer agent
λ DNA HindIII digest
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
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2nd Anticancer agent
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)

[Caffeine]
1.36 mM (100X)
13.6 mM (1000X)
50 mM (3676X)
0.22 mM (10X)
2.2 mM (100X)
22 mM (1000X)
50 mM (2273X)
0.132 mM (1X)
1.32 mM (10X)
13.2 mM (100X)
50 mM (379X)
0.0877 mM (10X)
0.877 mM (100X)
8.77 mM (1000X)
50 mM (5705X)
12.8 mM (100X)
50 mM (392X)

Table 3.44: Volume and Apparent Size of Supercoiled Bands in Figure 3.22.

Lane
2
3
4
5
6
7
8
9
10
11

Volume
(Intensity)
29,475,844
16,180,977
21,553,048
24,204,260
22,075,529
none
none
none
none
26,050,805

Apparent
size (bp)
3,095.58
3,060.97
3,063.30
3,051.88
3,086.83
none**
none**
none**
none**
3,167.57

Lane
12
13
14
15
16
17
18
19
20
-

Volume
(Intensity)
27,697,404
36,507,237*
27,796,349
none
none
none
none
none
none
-

Apparent
size (bp)
3,179.65
3,179.54
3,191.67
none**
none**
none**
none**
none**
none**
-

*denotes a volume above the intensity threshold. ** denotes evidence of intercalation.
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CHAPTER FOUR

DISCUSSION

4.1 Analysis of assays containing individual anticancer agents
4.1.1 Caffeine
Although caffeine is known to reduce the effectiveness of some topoisomerase IIinhibiting anticancer agents [Larsen, et al., 1996] [Hill, 2011] [Traganos, et al., 1993], it
has also been shown to act as a topoisomerase antagonist itself [Shin, et al., 1990]. As
shown in Figure 4.1, higher concentrations (10 mM–50 mM in assay) can be seen to
inhibit the activity of the topoisomerase II enzyme. The apparent increase in molecular
weight of the supercoiled band indicates that caffeine intercalates into the plasmid DNA;
however, this result does not appear to be concentration-dependent in the range of
concentrations tested. Lane 3 of Figure 4.1, containing 50 mM caffeine, shows strong
topoisomerase II inhibition, with a supercoiled band volume above the threshold for its
corresponding uninhibited assay, and a slight blurring of the intermediate banding
pattern, which suggests that caffeine may support the formation of nicked DNA by also
acting as a topoisomerase poison. Lane 4, containing only 10 mM caffeine, shows less
topoisomerase II inhibition, with a supercoiled band volume below the intensity cutoff
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and no smearing to its intermediate banding pattern, marking it as the lowest inhibitory
concentration of caffeine. Caffeine concentrations on an order of magnitude with those
tested in other assays are displayed alongside relevant results for comparison in
subsequent figures.
It is worth noting that the maximum solubility of caffeine in water is 100 mM.
Because of this, and due to the necessity of a variety of other components in a standard
topoisomerase II assay, no assays in this body of work contain a concentration of caffeine
over 50 mM.

Figure 4.1. Topoisomerase II inhibition assays containing caffeine and enzyme. 1: 0.3
µg pBR322 plasmid DNA; 2: uninhibited enzyme control with two units of
topoisomerase II; 3: 50 mM caffeine in assay; 4: 10 mM caffeine in assay; 5: 1 mM
caffeine in assay; 6: 100 µM caffeine in assay; 7: 10 µM caffeine in assay.
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4.1.2 Berberine
Although previous studies have indicated that berberine does not inhibit the action
of human topoisomerase II [Kim, et al., 1998], the results of this study indicate that
berberine does possess the ability to inhibit topoisomerase II, although the effects of
caffeine on this interaction are inconclusive. Figure 4.2, and its associated content table
(Table 4.1) display a compilation of the conditions under which berberine was tested.
Previous studies have supported berberine’s intercalation into DNA with a non-specific
DNA-binding ability [Park, et al., 2004]; however, no concentration-dependent
intercalation was seen at the concentrations tested (Figure 4.2, Lanes 3–6), although all
lanes showed a very slight increase in molecular weight. 1% (w/v) berberine was not
tested, as its property of fluorescence interferes with densitometry analysis at high
concentrations (data not shown). A large degree of topoisomerase II inhibition was seen
in Lane 7, 0.1% (w/v) berberine (135 µM). 0.01% (w/v) berberine (13.5 µM, Lane 8)
was chosen as the minimum inhibitory concentration of berberine, due to the intermediate
appearance of topoisomerase-induced unwound plasmid bands and the volume (intensity)
of the supercoiled band (1.83-times the volume of the supercoiled band in its associated
uninhibited topoisomerase II assay lane). This is an order of magnitude higher than the
IC50 value for cytotoxicity determined by previous research (50.0 µM) [Hill, 2011].
Significant inhibition was not seen at lower tested concentrations (Lanes 9–10, 1.35 µM–
135 nM). This inhibition was believed to not be due to the presence of 1% DMSO in the
solvent, as shown by comparison to Lane 11). Also, the distinctiveness of the individual
fluorescence bands produced by stepwise unwinding of the plasmid DNA by
topoisomerase II even in the presence of inhibitory concentrations of berberine indicates
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that inhibition of enzyme activity is due to catalytic inhibition of topoisomerase II, not
the topoisomerase-poison mechanism. This is supported by previous research which
indicates that berberine does not act as a topoisomerase poison [Park, et al., 2004].

Figure 4.2. Compilation of topoisomerase II assay lanes containing berberine, with
controls. Lane contents shown in Table 4.1.
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Table 4.1: Lane Contents of Compilation of Topoisomerase II Assay Lanes Containing
Berberine, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

10-1% Berberine (1µL)
10-2% Berberine (1µL)
10-3% Berberine (1µL)
10-4% Berberine (1µL)
10-1% Berberine (1µL)
10-2% Berberine (1µL)
10-3% Berberine (1µL)
10-4% Berberine (1µL)
1% DMSO (1µL)
-2
10 % Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
-

[Caffeine]
in assay
13.5 µM (1X)
135 µM (10X)
1.35 mM (100X)
13.5 mM (1000X)
50 mM (3719X)
135 µM (10X)
1.35 mM (100X)
13.5 mM (1000X)
50 mM (3719X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

While lanes 12–16 of Figure 4.2 indicated that the presence of up to 50 mM
caffeine had no effect on DNA in the presence of berberine, an increase in the inhibition
of topoisomerase II was seen with the presence of both 13.5 mM and 50 mM caffeine in
addition to the minimum inhibitory concentration of berberine in the assay (Lanes 19 and
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20). However, after comparison with the effects of 10 mM and 50 mM caffeine on the
activity of the enzyme itself (Lanes 22 and 21, respectively), it cannot be said that this
increase in inhibition was due to any potentiation of the berberine by caffeine. Previous
research has shown that the addition of 1.03 mM caffeine can cause a ten-fold increase in
the required IC50 of berberine [Hill, 2011]. However, because the effects seen in Lanes
19 and 20 of Figure 4.2 may be due to the separate actions of both berberine and caffeine
on the topoisomerase enzyme, present data suggest that caffeine does not inhibit the
action of berberine at concentrations up to 50 mM (3719-times the concentration of
berberine in solution). The presence of any interaction between caffeine and berberine is
inconclusive.
4.1.3 Chelerythrine
Figure 4.3, and its associated content table (Table 4.2) contain a compilation of
the assays which contained the anticancer agent chelerythrine. A known DNA
intercalator [Bai, et al., 2006], chelerythrine caused an apparent increase in the molecular
weight of the pBR322 DNA at all concentrations tested (Figure 4.3, Lanes 3–7), with
unexpectedly increased intercalation (greater apparent molecular weight increase) at
lower concentrations (1.31 µM–131 nM added to Lanes 6–7, respectively). This could be
due to potential dimerization of chelerythrine, suggesting that in greater concentrations
chelerythrine has the tendency to bind to itself, preventing its ability to intercalate into
DNA. 1% (w/v) chelerythrine (1.31 mM) in the presence of topoisomerase II did not
show intercalation, suggesting that any chelerythrine molecules not bound to each other
in potential dimerization would be occupied by interaction with the topoisomerase
enzyme, without additional molecules available for intercalating into the plasmid DNA.
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Lower concentrations of chelerythrine continued to show intercalation in the presence of
enzyme. Lanes 8 and 9, containing 1.31 mM and 131 µM chelerythrine respectively,
showed full inhibition of the topoisomerase II enzyme. Lane 10, with the addition of
13.1 µM chelerythrine, displayed an intermediate level of topoisomerase inhibition with
its moderate banding pattern, and supercoiled band over three times the volume of the
supercoiled band of its associated uninhibited topoisomerase II assay. This inhibition was
not believed to be due to the presence of 1% DMSO in the solvent, as shown by
comparison to Lane 13. Thus, 0.01% (w/v) chelerythrine (13.1 µM) was chosen as the
minimum inhibitory concentration for further testing. It should be noted that this value is
two orders of magnitude higher than the cytotoxicity IC50 value determined by previous
research (9.21 µM) [Hill, 2011]. Also, the distinct pattern of banding visible as a result
of topoisomerase activity indicates that any inhibition is due to catalytic inhibition of the
topoisomerase II enzyme, not the topoisomerase-poison mechanism.

Figure 4.3. Compilation of topoisomerase II assay lanes containing chelerythrine, with
controls. Lane contents shown in Table 4.2.
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Table 4.2: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Chelerythrine, with Controls.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

pBR322 TopoII

ATP

Anticancer agent

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Chelerythrine (1µL)
10-1% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-3% Chelerythrine (1µL)
10-4% Chelerythrine (1µL)
1% Chelerythrine (1µL)
10-1% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-3% Chelerythrine (1µL)
10-4% Chelerythrine (1µL)
1% DMSO (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
-

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

[Caffeine]
in assay
13.03 µM (1X)
130.3 µM (10X)
1.303 mM (100X)
13.03 mM (1000X)
50 mM (3839X)
0.01303 (1X)
0.1303 (10X)
1.303 (100X)
13.03 mM (1000X)
50 mM (3839X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

As shown in Lanes 14–23 (Figure 4.3), caffeine had no effect on the intercalation
of chelerythrine into the DNA. The increase in enzyme inhibition seen in Lane 23, in the
presence of 50 mM caffeine, is believed to be due solely to the inhibitory effects of
caffeine itself (compared to Lane 24). Although previous in-vivo research indicated that
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1.03 mM caffeine could cause a slight increase in IC50 for chelerythrine from 32.1 µM to
37.4 µM, no reduction in either the intercalation of, or topoisomerase II inhibition by,
chelerythrine was seen as a result of the addition of caffeine in the concentrations tested.
4.1.4 Doxorubicin
Doxorubicin is well-known as a DNA intercalator [Pommier, et al., 2010] and
topoisomerase poison [Tewey, et al., 1984]. A compilation of the assays containing
doxorubicin are shown in Figure 4.4, along with its associated content table (Table 4.3).
While ultraviolet visualization of DNA treated with high concentrations of doxorubicin is
difficult due to competitive inhibition with the fluorescent dye ethidium bromide [Xie, et
al., 2003], addition of doxorubicin concentrations of 0.1% (w/v) (86.0 µM) and below do
show some visibility following ethidium bromide staining. Doxorubicin shows
concentration-dependent intercalation and DNA nicking in the absence of enzyme, as
shown by Lanes 4–7. When in assay with topoisomerase II, it was determined that 0.01%
(w/v) doxorubicin (8.60 µM, Lane 10) displayed the moderate level of topoisomerase II
inhibition and DNA visibility for further testing. Because the bands appear as a smear
along the gel, rather than distinct bands, at concentrations above 86.0 nM, it is believed
that this is evidence that the mechanism by which doxorubicin inhibits topoisomerase II
is the topoisomerase-poison method, rather than catalytic inhibition. Stabilization of the
cleavage complex results in nicked strands of DNA, rather than religated circular
plasmids. These nicked bands run indistinctly slower than their religated counterparts,
producing a blurring effect in the region between supercoiled and linear DNA fragment
sizes. An added concentration of 8.60 µM doxorubicin produces an indistinct banding
pattern (unlike lower concentrations, Lanes 11 and 12), and a band of supercoiled DNA
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indicating significant topoisomerase inhibition (unlike higher concentrations, Lanes 8 and
9). This inhibitory effect was not believed to be due to the presence of 1% DMSO in the
solvent, as shown by comparison with Lane 13.

Figure 4.4. Compilation of topoisomerase II assay lanes containing doxorubicin, with
controls. Lane contents shown in Table 4.3.
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Table 4.3: Lane Contents for Compilation of Topoisomerase II Assay Lanes Containing
Doxorubicin, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Doxorubicin (1µL)
10-1% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-3% Doxorubicin (1µL)
10-4% Doxorubicin (1µL)
1% Doxorubicin (1µL)
10-1% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-3% Doxorubicin (1µL)
10-4% Doxorubicin (1µL)
1% DMSO (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
-
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[Caffeine]
in assay
0.0086 mM (1X)
0.086 mM (10X)
0.86 mM (100X)
8.6 mM (1000X)
50 mM (5814X)
0.0086 mM (1X)
0.086 mM (10X)
0.86 mM (100X)
8.6 mM (1000X)
50 mM (5814X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

Caffeine can be seen to have an effect on the intercalation of doxorubicin into
DNA at its highest concentration in assay, 50 mM (Lane 18, Figure 4.4), as indicated by a
decrease in the apparent molecular weight of smeared banding pattern. In assays
containing topoisomerase II, caffeine can also be seen to reduce the intercalation of
doxorubicin into DNA (Lanes 22 and 23, at caffeine concentrations of 8.6 mM and 50
mM respectively). Previous research indicates that caffeine is known to lower the
effectiveness of doxorubicin [Larsen, et al., 1996], even causing an increase in
cytotoxicity IC50 from 11.4 µM to 31.7 µM (with the addition of 1.03 mM caffeine) [Hill,
2011]. This would imply that topoisomerase would not be as inhibited in the presence of
both doxorubicin and caffeine, and some restoration of topoisomerase activity would be
seen in assay. While increased enzyme activity was not visible with high concentrations
of caffeine in addition to the doxorubicin, it is worth noting that the supercoiled band
visible in an assay containing both doxorubicin and maximum concentration caffeine
(Lane 23) is significantly less intense than the supercoiled band of an assay containing
only 50 mM caffeine. This indicates that the inhibitory effect of combined doxorubicin
and caffeine is less than that of caffeine alone, but greater than that of doxorubicin alone.
The fact that the combined effect is less than that expected from the sum of the effects of
the individual agents implies that there is an interaction between the two compounds. As
previous research with computational molecular modeling has suggested that the planar,
aromatic structures of doxorubicin and caffeine bind to one another through π–π
interactions, it is believed that binding between the two compounds caused neither to
inhibit topoisomerase II as fully as the individual compounds alone.
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4.1.5 Sanguinarine
Although the alkaloid sanguinarine has not previously been shown to inhibit
topoisomerase II, present results indicate that this DNA intercalator does act as a
topoisomerase II poison. Figure 4.5, and its associated content table (Table 4.4) contain a
compilation of the assays which contained sanguinarine. As shown by Lanes 3–7,
sanguinarine intercalates into DNA in a concentration-dependent manner, with no
intercalation seen at 1.36 µM (0.001% w/v) and below (Lanes 6 and 7). When in the
presence of topoisomerase II, the addition of 1% (w/v) (1.36 mM) sanguinarine is a
potent topoisomerase II inhibitor (Lane 8). The addition of 0.1% (w/v) (136 µM)
sanguinarine (Lane 9) results in a slightly less intense supercoiled band, and a smeared
banding pattern and visible “nicked” band indicative of the topoisomerase poison
inhibition mechanism. Lower concentrations (Lanes 10–12) exhibit increasingly distinct
bands and a lack of a visible supercoiled band, and so 136 µM sanguinarine was chosen
as the minimum inhibitory concentration for further testing. This value is significantly
higher than the cytotoxicity IC50 observed by previous researchers (5.78 µM) [Hill,
2011], but is not thought to be due to the inhibitory effects of the 10% DMSO in the
solvent (see lane 13).
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Figure 4.5. Compilation of topoisomerase II assay lanes containing sanguinarine, with
controls. Lane contents shown in Table 4.4.
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Table 4.4: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Sanguinarine, with Controls.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

pBR322 TopoII

ATP

Anticancer agent

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-2% Sanguinarine (1µL)
10-3% Sanguinarine (1µL)
10-4% Sanguinarine (1µL)
1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-2% Sanguinarine (1µL)
10-3% Sanguinarine (1µL)
10-4% Sanguinarine (1µL)
10% DMSO (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
-

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

[Caffeine]
in assay
136 µM (1X)
1.36 mM (10X)
13.6 mM (100X)
50 mM (368X)
136 µM (1X)
1.36 mM (10X)
13.6 mM (100X)
50 mM (368X)
50 mM
10 mM
1 mM
100 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

The addition of caffeine causes only a slight decrease in sanguinarine’s ability to
intercalate into DNA, as seen in Lane 17 of Figure 4.5, although the volume of the
“nicked” band is less intense. Similarly, the presence of maximum concentration caffeine
(50 mM) in the presence of topoisomerase II caused only a slight decrease in
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sanguinarine intercalation, and a complete lack of any intermediate bands due to plasmid
unwinding, indicating full topoisomerase inhibition. Although previous research
indicated that the addition of caffeine (1.03 mM) could cause a slight increase in IC50 for
sanguinarine, from 5.78 µM to 6.66 µM [Hill, 2011], comparison with the inhibition
caused by 50 mM caffeine alone in Lane 22 suggests that, although caffeine may be
inhibiting the ability of sanguinarine to intercalate, the effect of caffeine on
sanguinarine’s ability to inhibit topoisomerase II is inconclusive.
4.1.6 Tingenone
The steady apparent weight of all supercoiled bands in assays containing
tingenone, and the visibility of distinct unwound-plasmid bands in lanes also containing
the topoisomerase II enzyme, confirm previous molecular docking studies suggesting that
tingenone is a non-intercalating catalytic inhibitor of topoisomerase II [Setzer, 2008]. As
shown in Figure 4.6, which compiles the excerpted assay lanes which contain tingenone,
and its associated contents table, Table 4.5, none of the tested concentrations of tingenone
have any intercalative ability (Lanes 3–7). Although the bands resulting from stepwise
plasmid unwinding in assays containing enzyme did show a slight “frowning” (edges of
the bands curved down) that is often indicative of intercalation, the consistency of the
apparent molecular weight of the supercoiled bands supports a lack of intercalative
binding. Concentrations of 1% and 0.1% (w/v) tingenone (1.19 mM and 119 µM,
respectively, Lanes 8 and 9) did show the ability to inhibit topoisomerase II activity,
while lower concentrations showed no inhibition. Thus, 119 µM tingenone was chosen
as the minimum inhibitory concentration for further testing, as its inhibition was not
believed to be due to the presence of 10% DMSO in the solvent (compare with Lane 13).
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Figure 4.6. Compilation of topoisomerase II assay lanes containing tingenone, with
controls. Lane contents shown in Table 4.5.
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Table 4.5: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Tingenone, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Tingenone (1µL)
10-3% Tingenone (1µL)
10-4% Tingenone (1µL)
1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Tingenone (1µL)
10-3% Tingenone (1µL)
10-4% Tingenone (1µL)
10% DMSO
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
-

[Caffeine]
in assay
119 µM (1X)
1.19 mM (10X)
11.9 mM (100X)
50 mM (421X)
119 µM (1X)
1.19 mM (10X)
11.9 mM (100X)
50 mM (421X)
50 mM
10 mM
1 mM
100 µM

10X
Buffer
2 µL
.
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

The addition of caffeine had no effect on the tingenone and DNA alone (Figure
4.6, Lanes 14-17). However, the addition of caffeine was able to slightly further inhibit
the activity of topoisomerase II when added to tingenone. Lanes 18 and 19 show faint
banding patterns (with no “frowning”) due to plasmid unwinding, with a decrease in
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banding visible by the presence of 1.19 mM caffeine and above, with no intermediate
bands seen in the presence of 11.9 mM or 50 mM caffeine (Lanes 20 and 21). When
comparing these results to the lack of inhibition caused by the presence of 1 mM caffeine
alone (Lane 24), it can be concluded that this increased inhibition of topoisomerase II
may be due to potentiation of the effects of tingenone by caffeine. However, it should be
noted that the supercoiled bands in Lanes 18–21 do not exceed the cutoff for significantly
greater intensity than the supercoiled band of their associated uninhibited lane when
tested, as the uninhibited supercoiled band was abnormally intense on the original result
(uninhibited reaction shown in Lane 2 is a control excerpt from another gel). Therefore,
further testing would be required to confirm the potential potentiation of tingenone by
caffeine.
4.1.7 Paclitaxel
Previous research has indicated that very low concentrations of paclitaxel (0.02–
500 nM) can stimulate topoisomerase II’s catalytic activity, while concentrations of 5 µM
or higher may inhibit topoisomerase II activity [Dhawan and Swaffar, 1999].
Concentrations from 5.85 nM to 58.5 µM were tested in this experiment, and none
showed any effect on the activity of topoisomerase II, whether to enhance or inhibit.
Figure 4.7 and its associated contents table, Table 4.6, show a compilation of all tested
assays containing paclitaxel. Lanes 3–7 of Figure 4.7 show that paclitaxel does not
intercalate into the DNA at all, as supported by the literature [Dhawan and Swaffar,
1999]. While the assay containing the highest available concentration of paclitaxel, 58.5
µM (0.1% w/v, Lane 8), does show slight inhibition of topoisomerase, this may be due
solely to the presence of 100% DMSO as the solvent (compare with Lane 13). No other
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difference was seen among the tested concentrations, other than increased band clarity
with lower concentrations.

Figure 4.7. Compilation of topoisomerase II assay lanes containing paclitaxel, with
controls. Lane contents shown in Table 4.6.
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Table 4.6: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Paclitaxel, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

10-1% Paclitaxel (1µL)
10-2% Paclitaxel (1µL)
10-3% Paclitaxel (1µL)
10-4% Paclitaxel (1µL)
10-5% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-2% Paclitaxel (1µL)
10-3% Paclitaxel (1µL)
10-4% Paclitaxel (1µL)
10-5% Paclitaxel (1µL)
100% DMSO (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
-

[Caffeine]
in assay
58.6 µM (1X)
586 µM (10X)
5.86 mM (100X)
50 mM (854X)
58.6 µM (1X)
586 µM (10X)
5.86 mM (100X)
50 mM (854X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

The addition of all available caffeine concentrations showed no effect other than
those that may be attributed to the caffeine alone–the presence of 50 mM caffeine in
combination with the addition of 0.1% (w/v) paclitaxel in 100% DMSO fully inhibited
the activity of topoisomerase II (Lane 21). Slight intercalation was seen in the assays
containing paclitaxel, enzyme, and caffeine, but this is believed to be due to the
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intercalation of caffeine only. Therefore, no interaction between caffeine and paclitaxel
could be observed.
4.1.8 Malvidin
Figure 4.8 (along with its associated table, Table 4.7), shows a compilation of all
tested assays containing malvidin. While malvidin has been shown to inhibit
topoisomerase II [Jo, et al., 2005], no evidence of such inhibition was seen during current
testing. While slight, concentration-dependent intercalation was seen in assays lacking
topoisomerase II (Figure 4.8, Lanes 3–6), only the highest concentration of malvidin
available (151 µM) showed any ability to inhibit the activity of topoisomerase II (Lane
7). Unfortunately, this inhibition can be attributed to the presence of 100% DMSO as the
solvent (compare to lane 12). Lower concentrations, 15.1 µM–15.1 nM (0.01%0.00001% w/v, in Lanes 8-11, respectively), show no inhibition or other effect on the
activity of the topoisomerase II enzyme.

Figure 4.8. Compilation of topoisomerase II assay lanes containing malvidin, with
controls. Lane contents shown in Table 4.7.
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Table 4.7: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Malvidin, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

10-1% Malvidin (1µL)
10-2% Malvidin (1µL)
10-3% Malvidin (1µL)
10-4% Malvidin (1µL)
10-1% Malvidin (1µL)
10-2% Malvidin (1µL)
10-3% Malvidin (1µL)
10-4% Malvidin (1µL)
10-5% Malvidin (1µL)
100% DMSO (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
10-1% Malvidin (1µL)
-

[Caffeine]
in assay
151 µM (1X)
1.51 mM (10X)
15.1 mM (100X)
50 mM (331X)
151 µM (1X)
1.51 mM (10X)
15.1 mM (100X)
50 mM (331X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

No effect on the DNA was seen in the presence of malvidin and caffeine in
combination, at any of the tested concentrations (Figure 4.8, Lanes 13–16). While only
very faint unwound bands and intense supercoiled bands were visible at all
concentrations of caffeine tested (Lanes 17–20), these results are consistent with the
addition of 151 µM malvidin in 100% DMSO, in the presence of the associated
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concentrations of caffeine. It should be noted that the volume (intensity) of the
supercoiled bands in these lanes do not cross the chosen inhibition intensity threshold in
comparison to the uninhibited assay’s supercoiled band on that gel, as the uninhibited
lane had an abnormally intense supercoiled band at that time. Slight intercalation in the
presence of caffeine was observed, but the existence of any interaction between caffeine
and malvidin is inconclusive.
4.1.9 Delphinidin
Figure 4.9 and its associated table, Table 4.8, show a compilation of all tested
assays containing malvidin, including confirmatory lanes. At the highest concentration,
1.65 mM, delphinidin can be seen to induce nicking in the pBR322 plasmid DNA (Figure
4.9, Lanes 3 and 12). This is supported by previous research that indicates that some
anthocyanidins possess the ability to cause double-stranded breaks in DNA in the absence
of any enzyme, due to their strong binding affinity for dsDNA [Habermeyer, et al., 2005].
Lower concentrations of the anticancer agent, 0.1% - 0.0001% (165 µM–165 nM,
respectively) show significant intercalation into the plasmid DNA in the absence of
enzyme (Lanes 4–7), with an apparent increase in intercalation at 165 nM. In the
presence of topoisomerase II, however, no intercalation effects could be seen until the
added concentration of delphinidin was at 165 nM (0.0001% w/v) and below (Lanes 14–
16). The blurred nicking pattern seen with 1% delphinidin was not observed in an assay
where 1% delphinidin was added in the presence of topoisomerase (Lanes 8 and 13),
suggesting that the interaction between the anticancer agent and the enzyme prevents the
delphinidin from binding strongly to the plasmid DNA. The distinct banding patterns
produced even by moderately inhibited topoisomerase II assays support previous research
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that delphinidin is a catalytic topoisomerase II inhibitor, not a topoisomerase poison
[Habermeyer, et al., 2005].
The intensity of the supercoiled bands in Lanes 8–11 (1.65 mM–1.65 µM
delphinidin added) precludes these lanes from being concentrations for further testing in
the event of potentiation by the addition of caffeine. Therefore, lower concentrations
(165 nM–1.65 nM, 10-4% - 10-6%, w/v, respectively) were tested. While the volume
(intensity) of the 165 nM-assay’s supercoiled band (Lane 14) did not exceed the cutoff
value established by its associated uninhibited assay, its moderately visible supercoiled
band and full unwound-plasmid banding pattern caused it to be chosen as the minimum
inhibitory concentration for further testing. This inhibition was not believed to be due to
the presence of 0.01% DMSO in the solvent, as seen by comparison with Lane 17.

Figure 4.9. Compilation of topoisomerase II assay lanes containing delphinidin, with
controls. Lane contents shown in Table 4.8.
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Table 4.8: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Delphinidin, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Delphinidin (1µL)
10-1% Delphinidin (1µL)
10-2% Delphinidin (1µL)
10-3% Delphinidin (1µL)
10-4% Delphinidin (1µL)
1% Delphinidin (1µL)
10-1% Delphinidin (1µL)
10-2% Delphinidin (1µL)
10-3% Delphinidin (1µL)
1% Delphinidin (1µL)
1% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-5% Delphinidin (1µL)
10-6% Delphinidin (1µL)
0.01% DMSO (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
10-4% Delphinidin (1µL)
-
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[Caffeine]
in assay
0.165 µm (1X)
1.65 µM (10X)
16.5 µM (100X)
16.5 µM (1000X)
1.65 mM (10,000X)
16.5 mM (100,000X)
50 mM (303,951X)
0.165 µm (1X)
1.65 µM (10X)
16.5 µM (100X)
16.5 µM (1000X)
1.65 mM (10,000X)
16.5 mM (100,000X)
50 mM (303,951X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

The addition of all concentrations of caffeine, from equimolar (0.165 µM in
solution to 50 mM) caused an apparent decrease in delphinidin intercalation, with a
decrease in apparent molecular weight at the higher concentrations of caffeine (Lanes 18–
24). Considering that caffeine itself shows intercalative properties, this data supports a
direct interaction between delphinidin and caffeine, preventing either from intercalating
into the plasmid DNA. In the presence of enzyme, however, intercalation is still strongly
present at caffeine concentrations of 165 nM–16.5 µM (Lanes 25–27), and decreases with
the addition of higher concentrations of caffeine (Lanes 28–31).
In addition to the increased apparent molecular weight, the addition of even
equimolar caffeine (Lane 25) increases the inhibition of topoisomerase II, as evidenced
by the increased intensity of the supercoiled band in Lanes 25–31 (although these bands
do not cross the threshold set by the unusually bright supercoiled band of their associated
uninhibited topoisomerase II assay). Comparison with the effects of the addition of
caffeine alone at similar concentrations (Lanes 32–36) suggests that the increase in
topoisomerase II inhibition is due to potentiation of the effects of delphinidin by caffeine.
Also, the evidence that the supercoiled bands become less intense as their apparent
molecular weight decreases indicates that the inhibition of topoisomerase II is related to
the ability of delphinidin to intercalate into the plasmid DNA, although the distinct
banding patterns that result imply that delphinidin does not interfere with the DNAtopoisomerase II cleavage complex.
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4.1.10 Ellipticine
The alkaloid ellipticine is known to intercalate into DNA [Kohn, et al., 1975], and
bind the topoisomerase II enzyme even in the absence of DNA. It is thought to not
interfere with the ability of topoisomerase to religate the double-strand breaks formed by
the enzyme, but instead to simply speed the process by which these double-stranded
breaks are formed [Froelich-Ammon, et al., 1995]. Figure 4.10, which shows a
compilation of all ellipticine-containing assay results along with its associated table,
Table 4.9, supports the strong intercalative ability of ellipticine. Lanes 3–7 indicate that
concentrations from 2.03 mM down to 203 nM show a large degree of intercalation that
is concentration-dependent, as well as an intense “nicked” band. When the same
concentrations of ellipticine are added to assays containing topoisomerase II enzyme,
both 2.03 mM and 203 µM concentrations result in total topoisomerase inhibition. It
should be noted that intercalation in these lanes (Lanes 8 and 9) is significantly less than
the intercalation of the same concentrations of ellipticine added in the absence of enzyme,
implying that interactions between ellipticine and the topoisomerase II enzyme itself
reduce the ability of ellipticine to intercalate into the plasmid DNA. At a concentration
of 0.01% (w/v) ellipticine (20.3 µM, Lane 10), intercalation is slightly greater and
topoisomerase II activity is partially restored. By concentrations of 2.03 µM and 203 nM
(Lanes 11 and 12), no supercoiled band is visible any longer, implying that
topoisomerase activity is fully restored. The blurred nature of the intermediate bands
visible in Lanes 10–12 indicates that double-stranded breaks or nicks are being formed by
topoisomerase II in the presence of ellipticine, implying that ellipticine does not act as a
catalytic inhibitor. This could support previous research that ellipticine increases the rate
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at which topoisomerase II forms double-stranded breaks, although it could also be
indicative of a topoisomerase poison. Because of its intermediate banding pattern and
supercoiled band above the required threshold, 0.01% (w/v) ellipticine (20.3 µM) was
chosen as the minimum inhibitory concentration for further testing. Its inhibitory effects
were not believed to be due to the presence of 1% DMSO in the solvent, as seen by
comparison to Lane 13. It should be noted that this chosen concentration is an order of
magnitude higher than the cytotoxicity IC50 established by previous research (12.8 µM)
[Hill, 2011].

Figure 4.10. Compilation of topoisomerase II assay lanes containing ellipticine, with
controls. Lane contents shown in Table 4.9.
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Table 4.9: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Ellipticine, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Ellipticine (1µL)
10-1% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-3% Ellipticine (1µL)
10-4% Ellipticine (1µL)
1% Ellipticine (1µL)
10-1% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-3% Ellipticine (1µL)
10-4% Ellipticine (1µL)
1% DMSO (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
-

123

[Caffeine]
in assay
20.3 µM (1X)
203 µM (10X)
2.03 mM (100X)
20.3 mM (1000X)
50 mM (2463X)
20.3 µM (1X)
203 µM (10X)
2.03 mM (100X)
20.3 mM (1000X)
50 mM (2463X)
50 mM
10 mM
1 mM
100 µM
10 µM

10X
Buffer
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

The addition of caffeine, even at equimolar concentrations (20.3 µM in assay)
caused a decrease in the ability of ellipticine to intercalate into the plasmid DNA. This
decrease in apparent molecular weight of both the supercoiled and nicked bands in lanes
without enzyme (14–18) increased at higher concentrations of caffeine (notably, 20.3
mM and 50 mM). Because the apparent molecular weight of these bands is lower than
both the individual assays containing equal concentrations of ellipticine and the
respective concentrations of caffeine, it can be surmised that caffeine and ellipticine
interact directly to prevent either from being able to intercalate into the plasmid DNA.
When in the presence of enzyme, the same effect on intercalation is observed. Lower
concentrations of caffeine, 20.3 µM and 203 µM, continue to show a full smear of
intermediate unwound plasmid bands, although this blurred region is fainter, and the
supercoiled band more intense, than the associated concentration of ellipticine without
caffeine. By the time the caffeine concentration in the assay is one hundred times that of
ellipticine (2.03 mM, Lane 21), the intermediate bands are no longer visible, implying
that topoisomerase II has been further inhibited. A similar concentration of caffeine (1
mM, Lane 26) has no effect on the activity of topoisomerase II, so the increase in
inhibition shown in Lane 21 can be inferred to be due to potentiation of ellipticine by
caffeine. This is contradictory to previous research, which indicates that the addition of
caffeine raises the cytotoxicity IC50 of ellipticine from 12.8 µM to 333 µM [Hill, 2011].
It should be noted that Lanes 19–21 all bear supercoiled bands with
approximately 1.75-times the volume of the supercoiled band in their associated
uninhibited topoisomerase II assay, while Lanes 22 and 23, which show less
intercalation, fall well short of the threshold. Assays containing higher concentrations of
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caffeine show a decreased intensity of their supercoiled bands, a continued lack of visible
intermediate bands, and decreased intercalation (Lanes 22 and 23); however, increased
enzyme inhibition at these concentrations could be due to the separate inhibitory effects
of caffeine itself.
4.1.11 Pelargonidin
Figure 4.11 and its associated table, Table 4.10, show a compilation of all tested
assays containing pelargonidin. At the highest concentration available, 1.63 mM,
pelargonidin can be seen to induce nicking in the pBR322 plasmid DNA (Figure 4.11,
Lane 3), in the absence of enzyme. As with delphinidin, this result is supported by
previous research that indicates that some anthocyanidins possess the ability to cause
double-stranded breaks in DNA in the absence of any enzyme Habermeyer, et al., 2005].
The apparent increase in molecular weight of the supercoiled band in Lane 5 and the
tilted position of the supercoiled bands in Lanes 4 and 6 are believed to not be due to
intercalation; instead, as will be discussed later, this banding pattern is believed to be due
to interference by chelerythrine running towards the negative cathode from the lower row
of wells in the electrophoresis gel (not shown). Otherwise, no intercalation is believed to
be present.
The addition of both 1% (w/v) and 0.1% (w/v) pelargonidin (1.63 mM and 163
µM, respectively) resulted in significant topoisomerase II enzyme inhibition, with both
supercoiled bands well above their intensity threshold (Lanes 8 and 9). Also, the addition
of 1% (w/v) pelargonidin in the presence of enzyme (Lane 8) did not result in the any
visible smearing resulting from DNA strand breakage, indicating that the interaction
between the topoisomerase II enzyme and pelargonidin interferes with the ability of
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pelargonidin to bind the plasmid DNA so strongly. Also, the distinct banding pattern
resulting from all partially inhibited topoisomerase II assays indicates than any effect
pelargonidin has would be as a catalytic inhibitor, not as a topoisomerase poison. No
significantly intense supercoiled bands were observed with the additions of 16.3 µM
pelargonidin or lower (Lane 10–12), and thus 3.26 mM was chosen as the minimum
inhibitory concentration for further testing. Any inhibition seen was believed not to be
due to the presence of 10% DMSO in the solvent, as shown by comparison with Lane 13.
As pelargonidin had not previously been shown to have any interaction with
topoisomerase II, this result is significant.

Figure 4.11. Compilation of topoisomerase II assay lanes containing pelargonidin, with
controls. Lane contents shown in Table 4.10.
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Table 4.10: Lane Contents for Compilation of Topisomerase II Assay Lanes Containing
Pelargonidin, with Controls.

Lane

pBR322

TopoII

ATP

Anticancer agent

[Caffeine]
in assay

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg
0.30µg

10X
Buffer
-

2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units
2 units

1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Pelargonidin (1µL)
10-3% Pelargonidin (1µL)
10-4% Pelargonidin (1µL)
1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Pelargonidin (1µL)
10-3% Pelargonidin (1µL)
10-4% Pelargonidin (1µL)
10% DMSO (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
-

163 µM (1X)
1.63 mM (10X)
16.3 mM (100X)
50 mM (307X)
163 µM (1X)
1.63 mM (10X)
16.3 mM (100X)
50 mM (307X)
50 mM
10 mM
1 mM
100 µM

2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL
2 µL

No effect on the DNA or pelargonidin was seen in the presence of any of the
concentrations of caffeine tested in the absence of enzyme. Following the addition of
pelargonidin and caffeine in the presence of enzyme, no difference is visible among
assays containing 163 µM–16.3 mM caffeine (Lanes 18–20), and the supercoiled bands
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are not significantly brighter than the supercoiled band of their associated uninhibited
topoisomerase II assay. Lane 21 shows increased topoisomerase inhibition in the
presence of 50 mM caffeine, though this could be due solely to the effect of caffeine as a
topoisomerase II inhibitor at that concentration. Therefore, any effect of caffeine on
pelargonidin is inconclusive.
4.2 Analysis of assays containing anticancer agents in combination
Because of the variety of ways in which the tested anticancer agents are capable
of affecting both the DNA and the topoisomerase II enzyme, nine of the tested
compounds were chosen for testing in combination, both with and without enzyme, to
analyze any potential interactions.
4.2.1 Effects of anticancer agents in combination without enzyme present
Figure 4.12 shows a compilation of the topoisomerase II assays containing
individual anticancer drugs at their chosen minimum inhibitory concentrations, without
topoisomerase II enzyme present. When compared to Figures 4.13 and 4.14, which
display the results of assays containing combinations of the anticancer agents at their
minimum inhibitory concentrations, interactions between the drugs can be observed.
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Figure 4.12. Compilation of the topoisomerase II assays containing individual anticancer
drugs at their chosen minimum inhibitory concentrations, without enzyme. Lane 1: 13.5
µM berberine in 1% DMSO; 2: 13.1 µM chelerythrine in 1% DMSO; 3: 8.60 µM
doxorubicin in 1% DMSO; 4: 136 µM sanguinarine in 10% DMSO; 5: 119 µM
tingenone in 10% DMSO; 6: 58.5 µM paclitaxel in 100% DMSO; 7: 165 nM
delphinidin in 0.01% DMSO; 8: 20.3 µM ellipticine in 1% DMSO; 9: 163 µM
pelargonidin in 10% DMSO. Berberine (B), Chelerythrine (C), Doxorubicin (Do),
Sanguinarine (S), Tingenone (T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E),
Pelargonidin (Pe)
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Figure 4.13. First topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations, without enzyme. Drug contents shown in Table
4.11. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone
(T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 4.11: Drug contents of First Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations, without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Anticancer agent #1
λ DNA HindIII digest
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
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Anticancer agent #2
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)

Figure 4.14. Second topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations, without enzyme. Drug contents shown in Table
4.12. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone
(T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 4.12: Drug contents of Second Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations, without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Anticancer agent #1
λ DNA HindIII digest
-1
10 % Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)

Anticancer agent #2
-1
10 % Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)

In Figure 4.13, the assays containing chelerythrine and doxorubicin (Lane 4) and
sanguinarine and doxorubicin (Lane 10) show equal intercalation and DNA nicking to
Figure 4.12 Lane 3, doxorubicin alone. This indicates that the DNA damage induced by
doxorubicin was not mediated by the addition of either chelerythrine or sanguinarine;
however, the fact that the addition of the other anticancer agents to doxorubicin did not
produce an apparent molecular weight greater than doxorubicin alone (as observed by the

133

location of the “largest” nicked band) indicates that the two drugs may compete for the
same intercalation sites, with doxorubicin possessing the higher binding affinity.
Figure 4.13 Lane 5 shows an assay combining chelerythrine and sanguinarine.
These two physically similar compounds appear to have different mechanism of action on
topoisomerase II; although both intercalate, chelerythrine appears to act as a catalytic
inhibitor while sanguinarine acts as a topoisomerase poison. The intercalation seen in
Lane 5 is greater than that displayed by either chelerythrine or sanguinarine alone (Figure
4.12, Lanes 2 and 4 respectively). This indicates that both drugs are able to intercalate,
either into the same sites but with more drugs present, or at different sites along the DNA.
No interaction is seen between the drugs.
Figure 4.13, Lanes 6, 7, and 9 show combinations of chelerythrine with the nonintercalating agents tingenone, paclitaxel, and pelargonidin. In each lane, the
intercalation is approximately equal to that of chelerythrine alone, indicating that there is
no interference with the intercalative ability of chelerythrine by the addition of these
other drugs.
Lane 8 of Figure 4.13 shows an intercalation greater than chelerythrine alone, but
less than ellipticine alone (Figure 4.12, Lane 8). This may suggest either a competition
between the drugs for the same binding sites along the DNA, or an interaction between
the drugs themselves.
Combinations of doxorubicin with tingenone and paclitaxel Figure 4.13, Lanes 11
and 12) show a slightly greater intercalation ability than that of doxorubicin alone, which
is interesting because neither tingenone nor paclitaxel is an intercalative drug. This
134

suggests a possible potentiating interaction between these anticancer agents and the
ability of doxorubicin to intercalate into DNA. This may be supported by the findings of
previous research which indicates that the use of both paclitaxel and doxorubicin during a
chemotherapy regimen may intensify the adverse side effects of doxorubicin [Jassem,
2001].
The combinations of doxorubicin with delphinidin and ellipticine (Figure 4.13,
Lanes 13 and 14, respectively) show intercalation greater than that of doxorubicin alone,
as expected by the addition of other intercalative agents. This suggests that both
delphinidin and ellipticine are capable of also intercalating into the plasmid DNA in the
presence of doxorubicin, either into different binding sites or into the same sites with
more frequent occurrence do to the overall increase in drug concentration. This suggests
no competition or interference between these anticancer agents.
All assays containing sanguinarine in combination show a slight smearing at the
top of the band, indicating that some DNA damage may be occurring due to
sanguinarine’s intercalation. The combination of sanguinarine with both tingenone and
paclitaxel is far greater than that of sanguinarine alone, despite the fact that tingenone and
paclitaxel are non-intercalators. Conversely, the addition of delphinidin and ellipticine to
sanguinarine produce similar apparent molecular weight results, although they are both
intercalators, with ellipticine a stronger intercalator than delphinidin. Although the
consistency of these results suggests that the majority of the observed effects are due to
the strong binding affinity of sanguinarine, the observation that the intercalative ability of
sanguinarine appears to be easily and equally enhanced deserves further study. Similarly,
the combination of sanguinarine with pelargonidin also shows intercalation greater than
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that of sanguinarine alone, although to a lesser degree than the aforementioned
combinations. While this is supported by the fact that pelargonidin was not shown to
intercalate into the plasmid DNA, the effectiveness of intercalation by sanguinarine still
appears enhanced.
On Figure 4.14, combinations of tingenone and paclitaxel (Lane 4), tingenone and
delphinidin (Lane 5), tingenone and pelargonidin (Lane 7), paclitaxel and delphinidin
(Lane 8), paclitaxel and pelargonidin (Lane 10), delphinidin and pelargonidin (Lane 12),
berberine and tingenone (Lane 17), berberine and paclitaxel (Lane 18), and berberine and
pelargonidin (Lane 20) all show no apparent intercalation. While tingenone, paclitaxel,
and pelargonidin do not show any intercalation on their own, and berberine shows only
very slight intercalative ability, the anomaly in this series is the consistency of the results
of assays containing delphinidin, which is an intercalator. This suggests that the ability
of delphinidin to intercalate in the presence of other anticancer agents is reduced,
possibly indicating a binding preference for drug molecules rather than the plasmid DNA.
Combination assays on Figure 4.14 containing ellipticine–tingenone and
ellipticine (Lane 6), paclitaxel and ellipticine (Lane 9), delphinidin and ellipticine (Lane
11, ellipticine and pelargonidin (Lane 13), and berberine and ellipticine (Lane 19)–all
show approximately equal intercalation and band smearing. This level of intercalation is
significantly lower than that of ellipticine alone (Figure 4.12, Lane 8), suggesting that
ellipticine is also prone to binding molecules other than the plasmid DNA when
combined with other anticancer agents.
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Also on Figure 4.14, the combinations of berberine and chelerythrine (Lane 14),
berberine and doxorubicin (Lane 15), and berberine and sanguinarine (Lane 16) all show
slight intercalation equal to the intercalative ability of chelerythrine, doxorubicin, and
sanguinarine individually. Because berberine is a very weak intercalator, its effects may
be combined but not observed in these assays. No interaction between these anticancer
agents is observed.
4.2.2 Effects of anticancer agents in combination, with enzyme present
Figure 4.15 shows a compilation of the topoisomerase II assays containing
individual anticancer drugs at their chosen minimum inhibitory concentrations, with the
topoisomerase II enzyme present. When compared to Figures 4.16 and 4.18, which
display the results of assays containing combinations of the anticancer agents at their
minimum inhibitory concentrations, the effects of the combined drugs on the activity of
topoisomerase II can be observed. Tables 4.13 and 4.14 display the drug contents of
Figures 4.16 and 4.18, respectively. Figures 4.17 and 4.19 are bar graphs comparing the
volume (intensity) of the supercoiled bands of the minimum inhibitory concentrations of
the anticancer agents individually (Figure 4.15) and in combination (Figures 4.16 and
4.18, respectively).
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Figure 4.15. Compilation of the topoisomerase II assays containing individual anticancer
drugs at their chosen minimum inhibitory concentrations, with enzyme. Lane 1: 13.5 µM
berberine in 1% DMSO; 2: 13.1 µM chelerythrine in 1% DMSO; 3: 8.60 µM
doxorubicin in 1% DMSO; 4: 136 µM sanguinarine in 10% DMSO; 5: 119 µM
tingenone in 10% DMSO; 6: 58.5 µM paclitaxel in 100% DMSO; 7: 165 nM
delphinidin in 0.01% DMSO; 8: 20.3 µM ellipticine in 1% DMSO; 9: 163 µM
pelargonidin in 10% DMSO. Contents also shown Table 3.16, with the exclusion of
malvidin. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S),
Tingenone (T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Figure 4.16. First topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations with enzyme. Drug contents shown in Table 4.13.
Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone (T),
Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 4.13: Drug contents of First Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations with Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Anticancer agent #1
λ DNA HindIII digest
-2
10 % Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
10-1% Sanguinarine (1µL)
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Anticancer agent #2
-2
10 % Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)

Figure 4.17. Volume (intensity) of supercoiled bands of assays containing anticancer
agents at minimum inhibitory concentrations, individually and in the combinations shown
in Figure 4.16. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S),
Tingenone (T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)

Figure 4.18. Second topoisomerase II assay of combinations of anticancer agents at
minimum inhibitory concentrations with enzyme. Drug contents shown in Table 4.14.
Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone (T),
Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Table 4.14: Drug contents of Second Topoisomerase II Assay of Combinations of
Anticancer Agents at Minimum Inhibitory Concentrations with Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Anticancer agent #1
λ DNA HindIII digest
-1
10 % Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-1% Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
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Anticancer agent #2
-1
10 % Paclitaxel (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-4% Delphinidin (1 µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)
10-1% Pelargonidin (1µL)
10-2% Chelerythrine (1µL)
10-2% Doxorubicin (1µL)
10-1% Sanguinarine (1µL)
10-1% Tingenone (1µL)
10-1% Paclitaxel (1µL)
10-2% Ellipticine (1µL)
10-1% Pelargonidin (1µL)

Figure 4.19. Volume (intensity) of supercoiled bands of assays containing anticancer
agents at minimum inhibitory concentrations, individually and in the combinations shown
in Figure 4.18. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S),
Tingenone (T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)

All assays containing doxorubicin in Figures 4.16 and 4.18 look similar (Lanes 4,
10–15 on Figure 4.16, Lane 15 on Figure 4.18), all showing greater topoisomerase II
inhibition than doxorubicin alone (Figure 4.15, Lane 3). This suggests that the activity of
doxorubicin is potentiated in the presence of other anticancer agents, although some, like
delphinidin, should reduce the effectiveness of doxorubicin by reducing the number of
cleavage complex intermediates at the tested concentrations [Esselen, et al., 2009].
Figure 4.16, Lane 5 shows a combination of chelerythrine and sanguinarine that
shows a slight inhibition in the activity of topoisomerase II, not by the reappearance of a
supercoiled band, but by a shifting of the intermediate bands towards the less-unwound
state. The degree of topoisomerase II inhibition shown is far less than either
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chelerythrine (Figure 4.15, Lane 2) or sanguinarine (Figure 4.15, Lane 4) alone, implying
an inhibitory interaction between these two drugs. As catalytic inhibitors would interfere
with the ability of topoisomerase poisons to effectively inhibit enzyme activity, it is
possible that the mechanisms of these drugs are not conducive to a combined enhanced
effect. Similarly, Lanes 15–20 on Figure 4.16 show no topoisomerase inhibition, save for
a decrease in the apparent molecular weight of the banding pattern for combinations with
pelargonidin, a result similar to that shown in Figure 4.13 (without enzyme). It should be
noted that the wavy, “dumbbell” appearances of chelerythrine lanes 5-7 and sanguinarine
lanes 15-20 are typical of an electrophoresis gel that has been run too quickly. However,
this gel was run at the standard voltage and time (60V for 7 hours), making this result an
anomaly.
No topoisomerase II inhibition was observed in combinations containing
chelerythrine and tingenone (Lane 6), chelerythrine and paclitaxel (Lane 7), or
chelerythrine and pelargonidin (Lane 9) on Figure 4.16. This indicates that the activity of
chelerythrine was inhibited by the addition of other anticancer agents, also rendering the
secondary drugs ineffective themselves. Further research would be required to
understand the interaction between these compounds.
The majority of the assays in Figure 4.18–tingenone and paclitaxel (Lane 4),
tingenone and delphinidin (Lane 5), tingenone and pelargonidin (Lane 7), paclitaxel and
delphinidin (Lane 8), paclitaxel and pelargonidin (Lane 10), delphinidin and pelargonidin
(Lane 12), berberine and tingenone (Lane 17), berberine and paclitaxel (Lane 18), and
berberine and pelargonidin (Lane 20)–show no inhibition of the topoisomerase II
enzyme. This result is unexpected for so many combinations, and deserves further study.
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Combinations in Figure 4.18 containing ellipticine and sanguinarine (Lanes 6, 9,
11, 16, and 19) continue to exhibit the characteristic, blurred pattern of “nicked” bands
typical of inhibition by a topoisomerase poison. Although these assays have not inhibited
topoisomerase II to the point of preserving the supercoiled band, the inhibitory activity of
both ellipticine and sanguinarine appear to remain active. Greater inhibition is seen in
lanes combining delphinidin and ellipticine (Lane 11) and ellipticine and pelargonidin
(Lane 13), although both delphinidin and pelargonidin are catalytic inhibitors and should
interfere with the ability of ellipticine to act as a topoisomerase poison.
Finally, the combination of berberine and chelerythrine (Lane 14, Figure 4.18)
exhibits a blurring pattern to its intermediate bands that is typically indicative of doublestrand breaks caused by a topoisomerase poison. However, both berberine and
chelerythrine act as catalytic topoisomerase II inhibitors. This result suggests an
interesting interaction between berberine and chelerythrine that should be studied further
at a later date.
4.2.3 Effects of selected anticancer agents in combination, without enzyme, with
caffeine.
Five anticancer agents–berberine, doxorubicin, tingenone, delphinidin, and
ellipticine, were selected for further study due to their interaction with one another in
combination and their response to the addition of caffeine. Figure 4.20 shows the
minimum inhibitory concentrations of these drugs without the presence of topoisomerase
II. Caffeine was previously shown to have no effect on the plasmid DNA, and thus is not
included. Figures 4.21 and 4.22 show assays combining pairs of anticancer drugs with
caffeine in the absence of enzyme.
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Figure 4.20. Compilation of selected topoisomerase II assays containing individual
anticancer drugs at their chosen minimum inhibitory concentrations, without enzyme.
Lane 1: 13.5 µM berberine in 1% DMSO; 2: 8.60 µM doxorubicin in 1% DMSO; 3: 119
µM tingenone in 10% DMSO; 4: 165 nM delphinidin in 0.01% DMSO; 5: 20.3 µM
ellipticine in 1% DMSO

Figure 4.21. First topoisomerase II assay containing combinations of anticancer agents
and caffeine, without enzyme. Drug and caffeine contents shown in Table 4.15.
Berberine (B), Delphinidin (De).
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Table 4.15: Drug and Caffeine Contents of First Topoisomerase II Assay Containing
Combinations of Anticancer Agents and Caffeine, without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13

1st Anticancer agent
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)

2nd Anticancer agent
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-4% Delphinidin (1 µL)
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[Caffeine]
0.338 mM (10X)
3.38 mM (100X)
33.8 mM (1000X)
50 mM (1481X)
0.205 mM (10X)
2.05 mM (100X)
20.5 mM (1000X)
50 mM (2444X)
28.9 mM (1000X)
50 mM (1730X)
13.9 mM (100X)
50 mM (359X)
0.136 mM (10X)

Figure 4.22. Second topoisomerase II assay containing combinations of anticancer
agents and caffeine, without enzyme. Drug and caffeine contents shown in Table 4.16.
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Table 4.16: Drug and Caffeine Contents of Second Topoisomerase II Assay Containing
Combinations of Anticancer Agents and Caffeine, without Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

1st Anticancer agent
-2
10 % Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)

2nd Anticancer agent
-4
10 % Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)

[Caffeine]
1.36 mM (100X)
13.6 mM (1000X)
50 mM (3676X)
0.22 mM (10X)
2.2 mM (100X)
22 mM (1000X)
50 mM (2273X)
0.132 mM (1X)
1.32 mM (10X)
13.2 mM (100X)
50 mM (379X)
0.0877 mM (10X)
0.877 mM (100X)
8.77 mM (1000X)
50 mM (5705X)
12.8 mM (100X)
50 mM (392X)

Combinations of berberine and ellipticine (Figure 4.21, Lanes 1–4) display the
level of intercalation characteristic of ellipticine until when in the presence of 33.8 mM
and 50 mM caffeine. At that point, as with the addition of caffeine to ellipticine alone,
caffeine interferes with the ability of ellipticine to intercalate into the plasmid DNA. This
is believed to be due to π–π molecular interactions between the planar molecules of
caffeine and ellipticine [Hill, 2011].
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Similarly, combinations of ellipticine and delphinidin (Figure 4.21, Lanes 5–8)
show slightly greater intercalation than ellipticine and berberine, presumably owing to the
intercalative abilities of both ellipticine and delphinidin. Again, the ability of these
compounds to intercalate into the DNA is inhibited in the presence of both 20.5 mM and
50 mM caffeine. Because the apparent molecular weight remains above the level of
ellipticine and berberine, it is possible that only the intercalation of ellipticine is affected,
and delphinidin remains able to intercalate into the plasmid DNA even in the presence of
caffeine.
The addition of caffeine appears to have no effect on the combination of
doxorubicin and ellipticine (Figure 4.21, Lanes 9 and 10). Similarly, the levels of
caffeine used with the assays containing a combination of ellipticine and tingenone
(Lanes 11 and 12) are high enough that they only show a slight decrease in intercalative
ability of ellipticine with the addition of 50 mM caffeine.
Assays containing a combination of berberine and delphinidin (Figure 4.21, Lane
13 and Figure 4.22, Lanes 3–5) show no change with an increasing concentration of
caffeine. All lanes show only slight intercalation, less than the level at which delphinidin
(Figure 4.20, Lane 4) is capable of intercalating into the DNA when by itself. The
consistent appearance of these lanes further suggests that the intercalative ability of
delphinidin is not affected by the addition of caffeine, or at least not in a concentrationdependent manner.
Assays containing a combination of berberine and doxorubicin retain the smeared
banding appearance consistent with doxorubicin alone, although the intercalative ability
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of doxorubicin appears to be lowered with the addition of caffeine (by comparison with
Figure 4.20, Lane 2, doxorubicin alone). A slight decrease in doxorubicin’s intercalative
effects is seen in the presence of 50 mM caffeine, Figure 4.22, Lane 9, although the DNA
damage does not appear to be mitigated. Similar results are observed in the combination
of doxorubicin and delphinidin (Lanes 14–17) and doxorubicin and tingenone (Lanes 18–
19).
Combinations of berberine and tingenone (Figure 4.22, Lanes 10–14), both of
which show no or little intercalative ability, do not appear affected by the addition of
caffeine.
4.2.4 Effects of selected anticancer agents in combination, with enzyme and caffeine.
Figure 4.23 shows the minimum inhibitory concentrations of these drugs without
the presence of topoisomerase II, as well as the relevant concentrations of caffeine in
solution. Figures 4.24 and 4.26 show assays combining pairs of anticancer drugs with
caffeine in the presence of topoisomerase II. Tables 4.17 and 4.18 display the drug
contents of Figures 4.24 and 4.26, respectively. Figures 4.25, 4.27 and 4.28 are bar
graphs comparing the volume (intensity) of the supercoiled bands of the minimum
inhibitory concentrations of the anticancer agents individually (Figure 4.23) and in
combination (Figures 4.24 and 4.26, respectively).
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Figure 4.23. Compilation of selected topoisomerase II assays containing individual
anticancer drugs at their chosen minimum inhibitory concentrations, and selected
concentrations of caffeine in assay, with enzyme. Lane 1: 13.5 µM berberine in 1%
DMSO; 2: 8.60 µM doxorubicin in 1% DMSO; 3: 119 µM tingenone in 10% DMSO; 4:
165 nM delphinidin in 0.01% DMSO; 5: 20.3 µM ellipticine in 1% DMSO; 6: 50 mM
caffeine in assay; 7: 10 mM caffeine in assay; 8: 1 mM caffeine in assay; 9: 100 µM
caffeine in assay. Berberine (B), Doxorubicin (Do), Tingenone (T), Delphinidin (De),
Ellipticine (E).
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Figure 4.24. First topoisomerase II assay containing combinations of anticancer agents
and caffeine, with enzyme. Drug and caffeine contents shown in Table 4.17. Berberine
(B), Delphinidin (De).
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Table 4.17: Drug and Caffeine Contents of First Topoisomerase II Assay Containing
Combinations of Anticancer Agents and Caffeine, with Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13

1st Anticancer agent
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Ellipticine (1µL)
10-2% Berberine (1µL)

2nd Anticancer agent
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-4% Delphinidin (1 µL)

[Caffeine]
0.338 mM (10X)
3.38 mM (100X)
33.8 mM (1000X)
50 mM (1481X)
0.205 mM (10X)
2.05 mM (100X)
20.5 mM (1000X)
50 mM (2444X)
28.9 mM (1000X)
50 mM (1730X)
13.9 mM (100X)
50 mM (359X)
0.136 mM (10X)

Figure 4.25. Volume (intensity) of supercoiled bands of assays containing anticancer
agents at minimum inhibitory concentrations, individually, comparable concentrations of
caffeine, and anticancer agents and caffeine in combination as shown in Figure 4.24.
Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S), Tingenone (T),
Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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Figure 4.26. Second topoisomerase II assay containing combinations of anticancer
agents and caffeine, with enzyme. Drug and caffeine contents shown in Table 4.18.
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Table 4.18: Drug and Caffeine Contents of Second Topoisomerase II Assay Containing
Combinations of Anticancer Agents and Caffeine, with Enzyme.

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

1st Anticancer agent
-2
10 % Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-2% Berberine (1µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)

2nd Anticancer agent
-4
10 % Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-4% Delphinidin (1 µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-2% Doxorubicin (1µL)
10-1% Tingenone (1µL)
10-1% Tingenone (1µL)
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[Caffeine]
1.36 mM (100X)
13.6 mM (1000X)
50 mM (3676X)
0.22 mM (10X)
2.2 mM (100X)
22 mM (1000X)
50 mM (2273X)
0.132 mM (1X)
1.32 mM (10X)
13.2 mM (100X)
50 mM (379X)
0.0877 mM (10X)
0.877 mM (100X)
8.77 mM (1000X)
50 mM (5705X)
12.8 mM (100X)
50 mM (392X)

Figure 4.27. Volume (intensity) of supercoiled bands of assays containing anticancer
agents at minimum inhibitory concentrations, individually, comparable concentrations of
caffeine, and anticancer agents and caffeine in combination as shown in Lanes 1—13 of
Figure 4.26. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S),
Tingenone (T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)

Figure 4.28. Volume (intensity) of supercoiled bands of assays containing anticancer
agents at minimum inhibitory concentrations, individually, comparable concentrations of
caffeine, and anticancer agents and caffeine in combination as shown in Lanes 14—19 of
Figure 4.26. Berberine (B), Chelerythrine (C), Doxorubicin (Do), Sanguinarine (S),
Tingenone (T), Paclitaxel (Pa), Delphinidin (De), Ellipticine (E), Pelargonidin (Pe)
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The combined effect of berberine and ellipticine (Figure 4.24, Lanes 1–4) is
greater than the individual effects of either berberine or ellipticine alone (Figure 4.23,
Lanes 1 and 5, respectively). There are less visible intermediately unwound plasmid
bands and a bright supercoiled band, which still displays the smearing pattern indicative
of a functioning topoisomerase poison. While it appears that both catalytic inhibition and
the topoisomerase poison mechanism may be active in this combination, the presence of
caffeine at 33.8 mM and 50 mM (Lanes 3 and 4) continues to have an inhibitory effect on
the intercalative properties of ellipticine. Unfortunately, the increased topoisomerase
inhibition in those assays may be due only to the addition of the inhibitory effects of
caffeine itself (compare to Figure 4.23, Lane 6). It should be noted, however, that this
decrease in intercalation also accompanies a decrease in smearing above the supercoiled
band and along the region for unwound plasmid bands, indicating that the caffeine may
also be interfering with ellipticine’s activity as a topoisomerase II poison.
Similar results are observed in Figure 4.24, Lanes 5–8, with the combination of
ellipticine and delphinidin. While these DNA bands appear to have a slightly greater
molecular weight, this can be attributed to the fact that delphinidin is a more effective
DNA intercalator than berberine. Again, the drug-inhibitory effects observed by the
addition of caffeine appear to affect both the intercalation and the poisoning caused by
ellipticine, though it is difficult to weigh these results against the enzymatically inhibitory
effects of caffeine alone. Again, delphinidin may be less affected by the addition of
caffeine than ellipticine.
The combined inhibitory effect of ellipticine and tingenone is greater than
ellipticine and its other chosen combinations (Figure 4.24, Lanes 11–12) as shown by
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both the volume of the supercoiled band and the accompanying smear pattern. This
effect was greatly enhanced by the addition of 50 mM caffeine, though this could be due
to either caffeine enhancing the combined effect of the drugs or simply adding its own
inhibitory effect. Subsequent strong inhibitory lanes featuring tingenone and berberine
(Figure 4.26, Lanes 10–13) also support the theory that caffeine enhances the inhibitory
effects of the anticancer agents, even at dosage levels below that at which caffeine
typically displays its own ability to inhibit topoisomerase II (full topoisomerase II
inhibition in Lanes 10 and 11, possibly due to combined effect of berberine and
tingenone or potentiation of tingenone due to caffeine).
All assays containing doxorubicin (Figure 4.24, Lanes 9–10 and Figure 4.26,
Lanes 6–9, 14–19) exhibit comparable levels of topoisomerase inhibition and DNA
nicking. Only at the highest level of caffeine addition (50 mM in assay) does the ability
of doxorubicin to intercalate into the DNA appear to be inhibited, as exhibited by the
apparent decrease in molecular weight of the smear patterns in Lane 10 (Figure 4.24) and
Lanes 9, 17, and 19 (Figure 4.26). As caffeine is a DNA intercalator itself, this decrease
is not believed to be due to the effects of the caffeine alone. Rather, it appears that, at
substantially high concentrations, caffeine is capable of binding to doxorubicin and
preventing it from intercalating into the DNA. This would imply that caffeine
concentrations near 50 mM, in relation to a doxorubicin concentration of 8.60 µM, is
sufficiently near the Kd threshold of binding between caffeine and doxorubicin, as this is
the concentration where enough doxorubicin will bind to caffeine instead of the plasmid
DNA and produce a visible difference in the banding pattern.
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Finally, the combination of berberine and delphinidin (Figure 4.24, Lane 13, and
Figure 4.26, Lanes 3–5) shows a steady increase in topoisomerase II inhibition with the
addition of greater concentrations of caffeine, greater than that which can be attributed to
the effect of the added caffeine alone. With each greater addition of caffeine, the
supercoiled band produced in that assay becomes more intense, and the quantity of linear
DNA produced by the topoisomerase II decreases. While no significant intercalation is
seen in these assays, the addition of caffeine has a clear and concentration-dependent
potentiating effect on this combination of drugs. The mechanism by which caffeine
would have such an effect with these anticancer agents is unknown, and warrants further
study.
4.3 Anomalies discovered and addressed
4.3.1 Addressing the use of DMSO as a solvent
Previous research [Ping, 1995] demonstrates the inhibitory effects of DMSO on
the activity of topoisomerase II. At the time, the effects of DMSO could be lowered to a
negligible level when adding 1 µL DMSO to a 20 µL total volume assay containing 2
units of topoisomerase II. However, in the current experiments, all attempts to adjust
both the quantity of enzyme (1–5 units topoisomerase II) and the volume (10 µL–30 µL,
maximum well size for smaller gels) of the reaction resulted in visible enzyme inhibition
by the addition of 1 µL DMSO. Due to the availability of several anticancer agents only
in solution with DMSO as the solvent (previously prepared for use in cytotoxicity
assays), it was not feasible to remake all solutions at maximum concentration in water.
Therefore, samples were diluted ten-fold into water, so that both the concentration of
anticancer agent and DMSO were reduced by an order of magnitude with each dilution.
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As shown in Figure 4.29, all dilutions containing less than 100% DMSO show no
significant inhibitory effect on topoisomerase II, implying that the effects of anticancer
agents in solutions of 10% DMSO or lower could be attributed solely to the actions of the
drugs.

Figure 4.29. Topoisomerase II inhibitory assays containing DMSO. 1: 100% DMSO; 2:
10% DMSO; 3: 1% DMSO; 4: 0.1% DMSO; 5: 0.01% DMSO

4.3.2 Interference by 1% chelerythrine
Twice, an anomalous banding pattern was seen in the upper lanes of an
electrophoresis gel. When seen in Figure 4.30, Lanes 2–4, this uneven increase in
molecular weight appeared in assays containing 100 µM, 10 µM, and 1 µM caffeine,
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respectively. When seen in Figure 4.31, Lanes 2–4, this pattern appeared in assays
containing 0.1%, 0.01%, and 0.001% (w/v) pelargonidin. Due to the abnormality yet
similarity of these patterns and their location on the gel, it was soon determined that this
was the result of 1% (w/v) chelerythrine (1.31 mM) loaded into a well in the lower row of
lanes on the electrophoresis gel. This indicates that chelerythrine is positively charged,
and when loaded in high concentrations resulting in free drug unbound to the enzyme or
DNA, it will run towards the negative cathode and physically impede the progress of the
DNA in the upper lanes. This issue was addressed by identifying the cause of the
abnormality and no longer loading 1% chelerythrine into a well on the lower half of the
electrophoresis gel.

Figure 4.30. Interference in caffeine lanes by 1% chelerythrine.
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Figure 4.31. Interference in pelargonidin lanes by 1% chelerythrine.
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CHAPTER FIVE

CONCLUSION

5.1 Topoisomerase II inhibition by anticancer agents
Topoisomerase II is an essential cellular enzyme used to unwind supercoiled
DNA by the creation of double-stranded breaks for the processes of replication and
transcription. Its essential nature makes it an ideal target for anticancer drugs,
particularly because proliferative cancer cells often must make more frequent use of
topoisomerase II than noncancerous cells do [Deweese and Osheroff, 2009]. Such
anticancer agents may either interfere with the catalytic activity of the enzyme, or may
intercalate into the DNA and stabilize the cleavage complex [Nitiss, 2009], creating
permanent double-stranded breaks in the DNA (the topoisomerase poison mechanism)
[Fortune and Osheroff, 2000]. A wide variety of chemotherapeutic agents designed to
target the topoisomerase II enzyme have been synthetically developed or isolated from
natural products. In this study, ten such anticancer agents (berberine, chelerythrine,
doxorubicin, sanguinarine, tingenone, paclitaxel, malvidin, delphinidin, ellipticine, and
pelargonidin) were studied through gel electrophoresis assays to determine their ability to
inhibit topoisomerase II activity. Minimum drug concentrations which, when added to a
topoisomerase II inhibition assay, were able to moderately inhibit the activity of
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topoisomerase II, were as follows: 13.5 µM berberine, 13.1 µM chelerythrine, 8.6 µM
doxorubicin, 136 µM sanguinarine, 119 µM tingenone, 58.5 µM paclitaxel, 151 µM
malvidin, 165 nM delphinidin, 20.3 µM ellipticine, and 163 µM pelargonidin. In this
study, delphinidin was the most potent inhibitor of topoisomerase tested, while paclitaxel
and malvidin showed no inhibitory effects greater than could be attributed to the presence
of 100% DMSO as the solvent.
As a result of the clarity of the DNA banding pattern after gel electrophoresis
resulting from the topoisomerase II inhibition assays, it was possible to distinguish
between catalytic and poisonous topoisomerase II inhibitors. Berberine, chelerythrine,
tingenone, delphinidin, and pelargonidin were found to be catalytic inhibitors of the
topoisomerase enzyme, while doxorubicin, sanguinarine, ellipticine were found to be
topoisomerase poisons. Several of these results were unexpected. Chelerythrine, an
analogue of sanguinarine, was assumed to be a topoisomerase poison due to its
intercalative ability, although it was not previously shown to inhibit topoisomerase II
[Bai, et al., 2006]. However, chelerythrine was found to catalytically inhibit
topoisomerase II. Conversely, sanguinarine, which was previously found only to affect
the localization of topoisomerase II in the cell [Holy, et al., 2006], was found to act as an
intercalative topoisomerase poison. Pelargonidin, which had not previously been known
to act as a topoisomerase II inhibitor, was shown to inhibit the catalytic activity of the
enzyme. The fact that pelargonidin and malvidin were confirmed as catalytic inhibitors
was contrary to previous literature which asserted that, due to the hydroxyl groups on
their B-rings, delphinidin and cyanidin were the only anthocyanidins that were capable of
acting as catalytic inhibitors of topoisomerase II [Jo, et al., 2006]. Although paclitaxel
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had previously been shown to act directly against the topoisomerase II enzyme, being too
bulky to intercalate into DNA, and to produce both potentiating (at 0.02 nM–500 nM)
and inhibitory (> 5 mM) effects based on concentration [Dhawan and Swaffar, 1999], the
current study showed no significant effect of paclitaxel on topoisomerase II at the
concentrations tested.
Conversely, several of the obtained results are supported by the literature.
Despite its ability to intercalate into DNA, berberine has been previously found not to act
as a topoisomerase poison [Park, et al., 2004]. This supports previous research indicating
that the antitumor activity of berberine is derived from catalytic inhibition of
topoisomerase II. Doxorubicin [Tewey, et al., 1984] had previously been shown to act as
a topoisomerase poison, and ellipticine was shown to intercalate into DNA and enhance
the frequency of double-stranded DNA breaks caused by topoisomerase, although it did
not interfere with the religation step [Froelich-Ammon, et al., 1995]. Malvidin, an
anthocyanidin previously known to inhibit topoisomerase II [Jo, et al., 2005], was
confirmed as a catalytic inhibitor, as was delphinidin, previously known as a catalytic
inhibitor [Habermeyer, et al., 2005]. Tingenone was also confirmed as a nonintercalative catalytic inhibitor of topoisomerase [Setzer, 2008].
When tested in combination, it was believed that catalytic and poisonous
topoisomerase inhibitors would inhibit the activity of one another, as a catalytic inhibitor
would prevent the formation of the double-stranded breaks by topoisomerase II required
of the topoisomerase poison mechanism [Shin, et al., 1990]. However, due to the binding
constants of the drugs for their targets and the concentrations at which the drugs are
administered, this may not always be the case. It was expected that paclitaxel would
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increase the inhibitory effects of doxorubicin [Jassem, et al., 2001], and that delphinidin
would mitigate the effects of doxorubicin and ellipticine [Esselen, et al., 2009]. Drug
interactions that were observed included sanguinarine and chelerythrine, with a reduced
combined inhibition (this supports the hypothesis that drugs with separate inhibitory
mechanisms may interfere with one another). Conversely, when in the presence of the
non-intercalators tingenone, paclitaxel, and pelargonidin, the intercalative ability of
sanguinarine appears enhanced. The mechanism by which this could occur is unknown.
Doxorubicin also shows an enhanced ability to inhibit topoisomerase II when in the
presence of any other drugs, although the mechanism is unknown. Delphinidin and
ellipticine showed a reduced ability to intercalate into DNA in the presence of any other
tested anticancer agents, suggesting a binding preference for other aromatic molecules
rather than the plasmid DNA. Many other drug combinations showed a reduced ability to
inhibit the activity of topoisomerase II, suggesting an interaction between the
compounds. However, because of the indirect method of observation provided by the
topoisomerase II assay, a separate method of study would be required to observe any
direct interaction between the drugs.
5.2 Caffeine modulation of anticancer agents against topoisomerase II
The xanthine alkaloid caffeine is known to interact with many planar, aromatic
anticancer agents and affect their ability to inhibit topoisomerase II [Traganos, et al.,
1993]. However, the effects of some topoisomerase II antagonists, such as etoposide, are
potentiated by the addition of caffeine [Lock, et al., 1994]. Caffeine is arguably one of
the most widely consumed drugs in the nation, as a single cup of coffee contains
approximately 100 mg of caffeine. The average American consumes about 150 mg of
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caffeine each day. Moderate consumption of coffee results in plasma caffeine levels of
26 µM [Arendash and Cao, 2010], making it essential that the effects of caffeine on any
administered drugs are understood.
Unfortunately, at concentrations nearing its maximum solubility of 100 mM (in
water), caffeine also acts as a topoisomerase II inhibitor [Shin, et al., 1990]. Therefore,
the concentrations necessary to observe effects on the anticancer agents often produced
inconclusive results, as effects on the enzyme could not be distinguished as owing to the
effect of the drugs, caffeine, or a combination thereof. However, it was clearly observed
that caffeine was able to affect the intercalative ability of doxorubicin, sanguinarine,
delphinidin, and ellipticine in the absence of enzyme. These interactions are presumably
due to π–π molecular interactions due to stacking of these aromatic molecules; however,
a direct interaction is not observable by the inhibition assay method employed in this
experiment. Direct observation of binding by a separate method, such as nuclear
magnetic resonance imaging, could provide evidence of direct interactions as well as
potentially establishing the concentration ranges at which these compounds are capable
of binding in significant quantities (Kd). These results should be verified further,
however, as caffeine concentrations as low as 0.1645 µM and 20.3 µM were shown to
inhibit the ability of delphinidin and ellipticine, respectively, to intercalate into DNA. As
moderate coffee consumption will produce a plasma caffeine concentration of 26 µM, the
results of this study suggest that the consumption of coffee during any chemotherapy
regimen utilizing delphinidin should be strictly limited.
Similarly, after compensating for the enzyme inhibitory effects of caffeine itself,
caffeine was also found to potentiate the effects of tingenone, delphinidin, and ellipticine,
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as well as the combination of berberine and delphinidin. Potentiation was observed in the
event that the inhibition of topoisomerase II was greater than that observed from the
anticancer agent and caffeine individually at the selected concentrations. These results
deserve further study by the anticancer community, because if concentrations of 2.03 mM
caffeine can make the effects of ellipticine stronger, as this research suggests, then
caffeine should not be administered in the event of an ellipticine overdose. Alternately,
caffeine could be administered in conjunction with the aforementioned potentiated
anticancer agents, allowing for equal anticancer effectiveness with lower concentrations
of drugs. However, these results are contrary to previous research which indicates that
caffeine lessens the side effects, and presumably the effectiveness, of ellipticine
[Traganos, et al., 1993]. Although previous research which indicates that caffeine
significantly raised the cytotoxicity IC50 of berberine and ellipticine, and slightly raised
the cytotoxicity IC50 of chelerythrine, doxorubicin, and sanguinarine, it should be noted
that a direct enzymatic assay like the topoisomerase II inhibitory assay contains very
different conditions and levels of topoisomerase II than a whole-cell cytotoxicity assay.
A summary of the relative inhibitory levels of the tested anticancer agents, their
ability to be affected by caffeine, and significant drug interactions is shown in Table 5.1.

169

Table 5.1: Summary of the Relative Inhibitory Levels of Tested Anticancer Agents,
Their Ability to be Affected by Caffeine, and Significant Drug Interactions.

Drug

Minimum
inhibitory
concentration

Affected by caffeine?

Berberine (B)

13.5 µM

Inconclusive, potentiates
combination with delphinidin

Chelerythrine
(C)

13.1 µM

Not at concentrations tested

Doxorubicin
(Do)

8.60 µM

Intercalation inhibited by 8.6 mM,
activity inhibited with 50 mM

Sanguinarine
(S)

136 µM

Intercalation slightly inhibited at
50 mM, inhibition of activity
inconclusive

Tingenone (T)
Paclitaxel (Pa)
Malvidin (M)

119 µM
58.5 µM
151 µM

Potentiation at 1.19 mM
Inconclusive
Inconclusive

Delphinidin
(De)

165 nM

Intercalation inhibited by 165 µM,
activity potentiated by 165 nM,

Ellipticine (E)

20.3 µM

Intercalation inhibited by 20.3 µM,
activity potentiated by 2.03 mM

Pelargonidin
(Pe)

163 µM

Inconclusive

Significant
interactions?
DNA damage
with C
Activity
inhibited by S
Intercalation
potentiated by
T and Pa,
activity
potentiated by
all drugs
Intercalation
potentiated by
T, Pa, De, and
E
Not tested
Intercalation
inhibited by
other drugs
Intercalation
inhibited by
other drugs
-

5.3 Future direction
The evaluation of the effects of caffeine on the ability of certain anticancer agents
to affect the enzyme topoisomerase II has yielded interesting and encouraging results.
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Further information could be discovered about the interactions of these drugs with the
enzyme, caffeine, and one another with further study. Potential subjects for future study
include:
1.) Testing additional combinations of drugs not chosen for further study at this
time. This could reveal further drug interactions and their ability to interact
with caffeine.
2.) Cytotoxicity studies. Although the cytotoxic effects of six of these
compounds were evaluated previously [Hill, 2011], the effects in vivo of the
other four remain to be seen at this institution.
3.) Nuclear magnetic resonance (NMR) studies to potentially observe any
direction interactions between caffeine and the anticancer agents. The
research method employed in this study, while capable of providing many
valuable insights into the function of these anticancer agents, is a highly
indirect method of observing the interaction between drugs and caffeine.
Rather than observing how caffeine modulates the ability of an anticancer
agent to affect an enzyme’s ability to produce a change in DNA and inferring
an interaction between caffeine and the drug, it would be prudent to employ a
method which could indicate directly if there was binding between the drugs
and caffeine. NMR would provide a more direct method of observation for
any potential binding events.
4.) Other anticancer agents or natural products could be tested to determine their
effect on topoisomerase II and their ability to be affected by the addition of
caffeine.
171

172

173

REFERENCES

Affymetrix, Inc. Topoisomerase II, Alpha. Product information.
www.usb.affymetrix.com. 2014.
Affymetrix, Inc. Topoisomerase II, Alpha. Relaxation of supercoiled DNA protocol.
www.usbweb.com. 2009.
Aimova, D., Svobodova, L., Kotrbova, V., Mrazova, B., Hodek, P., Hudecek, J.,
Vaclavikova, R., Frei, E., and Stiborova, M. The anticancer drug ellipticine is a
potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own
metabolism. Drug Metabolsim & Disposition, 35(10): 1926-1934, 2007.
Alexander, R.B., Isaacs, J.T., and Coffey, D.S. Tumor necrosis factor enhances the in
vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA
topoisomerase II in the treatment of murine bladder cancer. J of Urology, 138(2):
427-429, 1987.
Bai, L.P., Zhao, Z.Z., Cai, Z., and Jiang, Z.H. DNA-binding affinities and sequence
selectivity of quaternary benzophenanthridine alkaloids sanguinarine,
chelerythrine, and nitidine. Bioorg & Med Chem., 14(16): 5439-5445, 2006.
Baldwin, E. L., and Osheroff, N. Etoposide, topoisomerase II and cancer. Curr Med
Chem Anticancer Agents, 5: 363-372, 2005.
Barth, M.C., Dederich, D.A., and Dedon, P.C. BioTechniques, 47(1): 633-635, 2009.

174

Basu, P., Bhowmik, D., Suresh Kumar, G. The benzophenanthridine alkaloid
chelerythrine binds to DNA by intercalation: Photophysical aspects and
thermodynamic results of iminium versus alkanolamine interaction. J of
Photochemistry and Photobiology B: Bio., 129: 57-68, 2013.
Bei, R., Masuelli, L., Turriziana, M., Volti, G.L., Malaguarnera, M., and Galvano, F.
Impaired expression and function of signaling pathway enzymes by anthocyanins:
role on cancer prevention and progression. Curr Enzyme Inhibition, 5: 184-197,
2009.
Bodley, A., Liu, L.F., Israel, M., Seshadri, R., Koseki, Y., Guiliani, F.C., Kirschenbaum,
S., Silber, R., and Potmesil, M. DNA topoisomerase II-mediated interaction of
doxorubicin and daunorubicin congeners with DNA. Cancer Res., 49: 5969-5978,
1989.
Bognar, E., Sarszegi, Z., Szabo, A., Debreceni, B., Kalman, N., Tucsek, Z., Sumegi, B.,
and Gallyas, F. Antioxidant and anti-inflammatory effects in RAW254.7
macrophages of malvidin, a major red wine polyphenol. PLOS ONE, 8(6), 2013.
Brinker, A.M., Ma, J., Lipskey, P.E., and Raskin, I. Medicinal chemistry and
pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 68(6),
2007.
Brown, P.M., Moir, M., Thomson, R.H., King, T.J., Krishnamoorthy, V., and Seshadri,
T.R. Tingenone and hydroxytingenone, triterpenoid quinine methods from
Euonymus tingens. J Chem Soc., 1: 2721-2725, 1973.

175

Capranico, G., Kohn, K.W., and Pommier, Y. Local sequence requirements for DNA
cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucl
Acids Res., 18(22): 6611-6619, 1990.
Chen, C.Y., Wang, C.H., and Chen, A.H. Recognition of molecularly imprinted
polymers for a quaternary alkaloid of berberine. Talanta, 84(4): 1038-1046, 2011.
Chen, N.T., Wu, C.Y., Chung, C.Y., Hwu, Y., Cheng, S.H., Mou, C.Y., and Lo, L.W.
Probing the dynamics of doxorucicin-DNA intercalation during the activation of
apoptosis by fluorescence lifetime imaging microscopy (FLIM). PLoS ONE,
7(9): e44947, 2012.
Chen, Y., Wan, Y., Wang, Y., Zhang, H., and Jiao, Z. Anticancer efficacy enhancement
and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles.
Int J Nanomedicine., 6: 2321-2326, 2011.
Chmura, S.J., Dolan, M.E., Cha, A., Mauceri, H.J., Kufe, D.W., and Weichselbaum, R.R.
In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride
induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res., 6: 737742, 2000.
Chow, A.Y. Cell cycle control by oncogenes and tumor suppressors: driving the
transformation of normal cells into cancerous cells. Nature Education, 3(9): 7,
2010.
Cole, S.P.C., Chanda, E.R., Dicke, F.P., Gerlach, J.H., and Mirski, S.E.L. Non-Pglycoprotein-mediated multidrug resistance in a small cell lung cancer cell line:
evidence for decreased susceptibility to drug-induced DNA damage and reduced
levels of topoisomerase II. Cancer Res., 51: 3345-3352, 1991.

176

Collins, K., Jacks, T., and Pavletich, N.P. The cell cycle and cancer. PNAS, 94: 27762778, 1997.
Cretu, G., Morlok, G., and Nechifor, G. Development of a quantitative high performance
thin layer chromatographic method for analysis of delphinidin 3-glucoside in
berry extracts. U.P.B. Sci Bull., 75(4): 69-78, 2013.
Cushnie, T.P.T., and Lamb, A.J. Antimicrobial activity of flavonoids. Int J of
Antimicrobial Agents, 26: 343-356, 2005.
Davies, D.B., Veselkov., D.A., Djimant, L.N., and Veselkov, A.N. Hetero-association of
caffeine and aromatic drugs and their competitive binding with a DNA oligomer.
Eur Biophys J., 30: 354-366, 2001.
Deweese, J. E., and Osheroff, N. The DNA cleavage reaction of topoisomerase II: wolf
in sheep’s clothing. Nucleic Acids Res., 37: 738-748, 2009.
Dharmananda, S. New uses of berberine: a valuable alkaloid from herbs for “damp-heat”
syndromes.” Institute for Traditional Medicine, Portland, Oregon.
<http://www.itmonline.org/articles/berberine/berberine.htm>. 2005.
Dhawan, V., and Swaffar, D.S. A unique paclitaxel-mediated modulation of the catalytic
activity of topoisomerase IIalpha. Anticancer drugs, 10(4): 397-404, 1999.
Doisneau-Sixou, S.F., Sergio, C.M., Carroll, J.S., Hui, R., Musgrove, E.A., and
Sutherland, R.L. Estrogen and antiestrogen regulation of cell cycle progression in
breast cancer cells. Endocrine-Related Cancer, 10: 179-186, 2003.
Donehower, R.C. The clinical development of paclitaxel: a successful collaboration of
academia, industry and the National Cancer Institute. The Oncologist 1(4): 240243, 1996.

177

Esselen, M., Boettler, U., Teller, N., Bachler, S., Hutter, M., Rufer, C.E., Skrbek, S., and
Marko, D. Anthocyanin-rich blackberry extract suppresses the DNA-damaging
properties of topoisomerase I and II poisons in colon carcinoma cells. J Agric
Food Chem., 59(13): 6966-6973, 2011.
Esselen, M., Fritz, J., Hutter, M., and Marko, D. Delphinidin modulates the DNAdamaging properties of topoisomerase II poisons. Chem Res Toxicol., 22(3):
554-564, 2009.
Evstigneev, M.P., Khomich, V.V., and Davies, D.B. Complexation of anthracycline
drugs with DNA in the presence of caffeine. Eur Biophys J., 36: 1-11, 2006.
Fortune, J. M., and Osheroff, N. Topoisomerase II as a target for anticancer drugs: when
enzymes stop being nice. Prog Nucleic Acid Res Mol Bio., 64: 221-253, 2000.
Freshney, R. Ian. Culture of Animal Cells, 6th ed. Wiley-Blackwell, Hoboken, New
Jersey. 463-464, 2010.
Fritz, J., Roth, M., Holbach, P., Esselen, M., and Marko, D. Impact of Delphinidin on the
maintenance of DNA integrity in human colon carcinoma cells. J Agric Food
Chem., 56(19): 8891-8896, 2008.
Froelich-Ammon, S.J., Patchan, M.W., Osheroff, N., and Thompson, R.B. Topisomerase
II binds to ellipticine in the absence or presence of DNA: characterization of
enzyme-drug interactions by fluorescence spectroscopy. J Bio Chem., 270:
14998-15004, 1995.
Giaccone, G., Gazdar, A.F., Beck, H., Zunino, F., and Capranico, G. Multidrug
sensitivity phenotype of human lung cancer cells associated with topoisomerase II
expression. Cancer Res., 52: 1666-1674, 1992.

178

Goldstein, E. Analysis of the repair of topoisomerase II DNA damage. Univ. of Central
Florida Underad Res J., 5:51-67, 2011.
Gomes, J.P.M., Cardoso, C.R.P., Varanda, E.A., Molina, J.M., Fernandez, M.F., Olea, N.,
Arlos, I.Z., and Vilegas, W. Antitumoral, mutagenic and (anti)estrogenic
activities of tingenone and pristimerin. Revista Brasileira de
Farmacognosia, 21(6): 963-971, 2011
Goodsell, D. Topoisomerases. RCSB: PDB-101. Molecule of the Month 73. 2006. <
http://www.rcsb.org/pdb/101/motm.do?momID=73>. Accessed April 2014.
Habermeyer, M., Fritz, J., Barthelmes, H.U., Christensen, M.O., Larsen, M.K., Boege, F.,
and Marko, D. Anthocyanidins modulate the activity of human DNA
topoisomerases I and II and affect cellular DNA integrity. Chem Res Toxicol.,
18: 1395-1404, 2005.
Hanahan, D., and Weinberg, R.A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
Hande, K.R. Etoposide: four decades of development of a topoisomerase inhibitor. Euro
J of Cancer. 34(10): 1514-1521, 1998.
Hengstler, J.G., Heimerdinger, C.K., Schiffer, I.B., Gebhard, S., Sagemuller, J., Tanner,
B., Bolt, H.M., and Oesch, F. Dietary topoisomerase II-poisons: contribution of
soy products to infant leukemia? EXCLI J., 1:8-14, 2002.
Herbert, J.M., Augereau, J.M., Gleve, J., and Maffrand, J.P. Chelerythrine is a potent and
specific inhibitor of protein kinase C. Biochem Biophys Res Commun., 172(3):
993-999, 1990.

179

Hill, G. π-π molecular interactions between intercalating antitumor agents and caffeine.
Thesis submitted to the Department of Chemistry and the School of Graduate
Studies at the University of Alabama in Huntsville. 2011.
Hill, G.M., Moriarity, D.M., and Setzer, W.N. Attenuation of cytotoxic natural product
DNA intercalating agents by caffeine. Sci Pharm., 79: 739-747, 2011.
Ho, Y.T., Yang., J.S., Lu, C.C., Chiang, J.H., Li, T.C., Lin, J.J., Lai, K.C., Liao, C.L.,
Lin, J.G., and Chung, J.G. Berberine inhibits human tongue squamous carcinoma
cancer tumor growth in a murine xenograft model. Phytomedicine, 16: 887-890,
2009.
Holm, C., Covery, J.M., Kerrigan, D., and Pommier, Y. Differential requirement of
DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in
Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
Holy, J., Lamont, G., and Perkins, E. Disruption of nucleocytoplasmic trafficking of
cyclin D1 and topoisomerase II by sanguinarine. BMC Cell Bio., 7(13), 2006
Hou, D.X., Kai, K., Li, J.J., Lin, S., Terahara, N., Wakamatsu, M., Fujii, M., Young,
M.R., and Colburn, N. Anthocyanidins inhibit activator protein 1 activity and cell
transformation: structure-activity relationship and molecular mechanisms.
Carcinogenesis, 25(1): 29-36, 2004.
Hsiang, Y.H., Hertzberg, R., Hecht, S., and Liu, L.F. Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Bio Chem., 260(27):
14873-14878, 1985.

180

Hsiang, Y.H., Lihou, M.G., and Liu, L.F. Arrest of replication forks by drug-stabilized
topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by
camptothecin. Cancer Res., 49: 5077, 1989.
Hsiang, Y.H., Liu, L.F. Identification of mammalian DNA topoisomerase I as an
intracellular target of the anticancer drug camptotecin. Cancer Res., 48: 17221726, 1988.
Huang, K.C., Gao, H., Yamaski, E.F., Grabowski, D.R., Liu, S., Shen, L.L., Chan, K.K.,
Ganapathi, R., and Snapka, R.M. Topoisomerase II poisoning by ICRF-193. J
Bio Chem., 276: 44488-44494, 2001.
Islam, M.M., Basu, A., and Kumar, G.S. Binding of 9-O-(ω-amino) alkyl ether
analogues of the plant alkaloid berberine to poly(A): insights into self-structure
induction. Med Chem Commun., 2: 631-637.
Jarvinen, T.A.H., Tanner, M., Rantanen, V., Barlund, M., Borg, A., Grenman, S., and
Isola, J. Amplification and deletion of topoisomerase IIα associate with erbB-2
amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in
breast cancer. Am J Pathol., 156(3): 839-847, 2000.
Jassem, J., Pienkowski, T., Pluzanska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z.,
Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., Munier, S., and Weil, C.
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and
cyclophosphamide as first-line therapy for women with metastatic breast cancer:
final results of a randomized phase III multicenter trial. J Clin Oncol., 19: 17071715, 2001.

181

Jensen, P.B., Sørensen, B.S., Demant, E. J. F., Sehested, M., Jensen, P. S., Vindeløv, L.,
and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of
etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small
cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Cancer Res., 50: 3311, 1990.
Jo, J.Y., Gonzales de Mejia, E., and Lila, M.A. Cytotoxicity of bioactive polymeric
fractions from grape cell culture on human hepatocellular carcinoma, murine
leukemia and non-cancerous PK15 kidney cells. Food and Chem Tox., 44: 17581767, 2006.
Jo, J.Y., Gonzales de Mejia, E., and Lila, M.A. Effects of grape cell culture extracts on
human topoisomerase II catalytic activity and characterization of active fractions.
J Agric Food Chem., 53(7): 2489-2498, 2005.
Kansal, V.K. and Potier, P. The biogenetic, synthetic and biochemical aspects of
ellipoticine, and antitumor alkaloid. Tetrahedron, 42(9), 2389-2408, 1986.
Khandelwal, N., and Abraham, S.K. Intake of anthocyanidins pelargonidin and cyanidin
reduces genotoxic stress in mice induced by diepoxybutane, urethane and
endogenous nitrosation. Pharmacology, 37(2): 837-843, 2014.
Kim, S.A., Kwon, Y., Kim, J.H., Muller, M.T., and Chung, I.K. Induction of
topoiosomerase II-mediated DNA cleavage by a protoberberine alkaloid,
berberrubine. Biochem., 37: 16316-16324, 1998.
Klenin, K., and Langowski, J. Computation of writhe in modeling of supercoiled
DNA. Biopolymers, 54: 307–317, 2000.

182

Kohn, K.W., Waring, M.J., Glaubiger, D., and Friedman, C.A. Intercalative binding of
ellipticine to DNA. Cancer Res., 35: 71-76, 1975.
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan,
H., Wang, S., Wu, J., Wang Y., Li, Z., Liu, J., and Jiang, J.D. Berberine is a
novel cholesterol-lowering drug working through a unique mechanism distinct
from statins. Nature Medicine, 10(12): 1344-1351, 2004.
Kosina, P., Walterova, D., Ulrichova, J., Lichnovsky, V., Stilborova, M., Rydlova, H.,
Vicar, J., Krecman, V., Brabec, M.J., and Simanek, V. Sanguinarine and
chelerythrine: assessment of safety on pigs in ninety days feeding experiment.
Food and Chem Tox., 42(1): 85-91, 2004.
Krishnan, P., and Bastow, K.F. The 9-position in berberine analogs is an important
determinant of DNA topoisomerase II inhibition. Anticancer Drug Des., 15(4):
255-264, 2000.
Kuo, C.L., Chou, C.C., and Yung, B.Y.M. Berberine complexes with DNA in the
berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Letters,
93(2): 193-200, 1995.
Lamy, S., Beaulieu, E., Labbe, D., Bedard, V., Moghrabi, A., Barrette, S., Gingras, D.,
and Beliveau, R. Delphinidin, a dietary anthocyanidin, inhibits platelet-derived
growth factor ligand/receptor (PDGF/PDGFR) signaling. Carcinogenesis, 29(5):
1033-1041, 2008.
Larsen, A.K., Escargueil, A.E., and Skladanowski, A. Catalytic topoisomerase II
inhibitors in cancer therapy. Pharm & Therap., 99(2): 167-181, 2003.

183

Larsen, R.W., Jasuja, R., Hetzler, R.K., Muraoka, P.T., Andrada, V.G., and Jameson,
D.M. Spectroscopic and molecular modeling studies of caffeine complexes with
DNA intercalators. Biophys J., 70: 443-452, 1996.
Letasiova, S., Jantova, S., Miko, M., Ovadekova, R., and Horvanthova, M. Efefct of
berberine on proliferation, biosynthesis of macromolecules, cell cycle and
induction of intercalation with DNA, dsDNA damage and apoptosis in Ehrlich
ascites carcinoma cells. J Pharm and Pharm., 58: 263-270, 2006.
Li, T.K. and Liu, L.F. Tumor cell death induced by topoisomerase-targeting drugs. Ann
Rev of Pharm and Tox., 41: 53-77, 2001.
Liu, Z., Liu, Q., Xu, B., Wu, J., Guo, C., Zhu, F., Yang, Q., Gao, G., Gong, Y., and Shao,
C. Berberine induces p53-dependent cell cycle arrest and apoptosis of human
osteosarcoma cells by inflicting DNA damage. Mut Res., 662: 75-83, 2009.
Lock, R.B., Galperina, O.V., Feldhoff, R.C., and Rhodes, L.J. Concentration-dependent
differences in the mechanism by which caffeine potentiates etoposide cytotoxicity
in HeLa cells. Cancer Res., 54: 4933-4939, 1994.
Malikova, J., Zdarilova, A., and Hlobilkova, A. Effects of sanguinarine and chelerythrine
on the cell cycle and apoptosis. Biomed Pap Med Fac Univ Palacky Olomouc
Czech Repub., 150(1): 5-12, 2006.
Mann, J. Natural products in cancer chemotherapy: past, present, and future. Nature
Reviews: Cancer, 2: 143-148, 2002.
Markovits, J., Linassier, C., Fosse, P., Couprie, J., Pierre, J., Jacquemin-Sablon, A.,
Saucier, J.M., le Pecq, J.B., and Larsen, A.K. Inhibitory effects of the tyrosine

184

kinase inhibitor Genistein on mammalian DNA topoisomerase II. Cancer Res.,
49: 5111-5117, 1989.
Marx, G., Zhou, H., Graves, D. E., and Osheroff, N. Covalent attachment of ethidium to
DNA results in enhanced topoisomerase II-mediated DNA cleavage. Biochem.,
50: 15884-15891, 1997.
McClendon, A.K., and Osheroff, N. DNA topoisomerase II, genotoxicity, and cancer.
Mutat Res., 623: 83-97, 2007.
McClendon, A.K., Rodriguez, A.C., and Osheroff, N. Human topoisomerase IIalpha
rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead
of replication forks. J Biol Chem., 280(47): 39337-39345, 2005.
McDowall, J. DNA Topoisomerase. Protein of the Month, InterPro.
<http://www.ebi.ac.uk/interpro/potm/2006_1/Page1.htm>. Accessed April 2014.
Medline Plus. Doxorubicin. National Institutes of Health.
<http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682221.html>. 2012.
Megyesi, M., and Biczok, L. Berberine alkaloid as a sensitive fluorescent probe for bile
salt aggregates. J Phys Chem B., 111(20): 5635-5639, 2007.
Mirtoselect. Anthocyanins vs anthocyanidins. Indena.
<http://www.mirtoselect.info/public/ anthocyanins.asp>. Accessed June 2014.
Musgrove, E.A., Hamilton, J.A., Lee, C.S., Sweeney, K.J., Watts, C.K., and Sutherland,
R.L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene
expression associated with changes in T-47D human breast cancer cell cycle
progression. Mol Cell Biol., 13(6): 3577-3587, 1993.

185

Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer.,
9(5): 338-350, 2009.
Norton, K.J. Phytochemicals–12 health benefits of delphinidin. Phytochemicals in
Foods. <http://womenhealthphytochemicals.blogspot.com/2011/12/phytochemicals-12-health-benefitsof.html>. 2011.
O’Malley, F.P., Chia, S., Tu, D., Shepherd, L.E., Levine, M.N., Bramwell, V.H.,
Andrulis, I.L., and Pritchard, K.I. Topoisomerase II alpha and responsiveness of
breast cancer to adjuvant chemotherapy. J Natl Cancer Inst., 101(9): 644-650,
2009.
Padget, K., Pearson, A.D.J., and Austin, C.A. Quantitiation of DNA topoisomerase IIα
and β in human leukaemia cells by immunoblotting. Leukemia, 14: 1997-2005,
2000.
Paixao, J., Dinis, T.C., and Almeida, L.M. Protective role of malvidin-3-glucoside on
peroxynitrite-induced damage in endothelial cells by counteracting reactive
species formation and apoptotic mitochondrial pathway. Oxid Med Cell Longev.,
2012.
Park, H.S., Kim, E.H., Sung, Y.H., Kang, M.R., Chung, I.K., Cheong, C., and Lee, W.
DNA binding mode of the isoquinoline alkaloid berberine with the
deoxyoligonucleotide d(GCCGTCGTTTTACA)2. Bull Korean Chem Soc., 25(4):
539-544, 2004.

186

Park, K., Kim, J., Lim, S., and Han, S. Topoisomerase II-α (topoII) and HER2
amplification in breast cancers and response to preoperative doxorubicin
chemotherapy. Euro J of Cancer, 39(5): 631-634, 2003.
Patel, K., Jain, A., and Patel, D.K. Medicinal significance, pharmacological activities,
and analytical aspects of anthocyanidins “delphinidin”: a concise report. J Acute
Disease, 2(3): 169-178, 2013.
Piosik, J., Gwizdek-Wisniewska, A., Ulanowska, K., Ochocinski, J., Czyz, A., Wegrzyn
G. Methylxanthines (caffeine, pentoxifylline and theophylline) decrease the
mutagenic effect of daunomycin, doxorubicin and mitoxantrone. Acta Biochim
Pol., 52(4): 923-926, 2005.
Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer,
6(10): 789-802, 2006.
Pommier, Y., Leo, E., Zhang, H. L., and Marchand, C. DNA topoisomerases and their
poisoning by anticancer and antibacterial drugs. Chemistry and Biology, 17: 421433, 2010.
Pommier, Y., Leo, E., Zhang, H., and Marchand, C. DNA topoisomerases and their
poisoning by anticancer and antibacterial drugs. Chem Biol., 17(5): 421-433,
2010.
Quintieri, A.M., Baldino, N., Filice, E., Seta, L., Vitetti, A., Tota, B., De Cindio, B.,
Cerra, M.C., and Angelone, T. Malvidin, a red wine polyphenol, modulates
mammalian myocardial and coronary performance and protects the heart against
ischemia/reperfusion injury. J Nutr Biochm., 24(7): 1221-1231, 2013.

187

Ross, J.A., Potter, J.D., Reaman, G.H., Pendergrass, T.W., and Robison, L.L. Maternal
exposure to potential inhibitors of DNA topoisomerase II and infant leukemia
(United State): A report from the Children’s Cancer Group. Cancer Causes &
Control, 7(6): 581-590, 1996.
Ross, W., Rowe, T., Glisson, B., Yalowich, J., and Liu, L. Role of topoisomerseII in
mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res., 44: 58575860, 1984.
RSCB Protein Data Bank. Human DNA topoisomerase I (70 Kda) in complex with the
poison camptothecin and covalent complex with a 22 base pair DNA duplex,
PDBID 1T8I. Primary citation: Staker, B.L., Feese, M.D., Cushman, M.,
Pommier, Y., Zembower, D., Stewart, L., and Burgin, A.B. Structures of three
classes of anticancer agents bound to the human topoisomerase I-DNA covalent
complex.
RSCB Protein Data Bank. Human topoisomerase II alpha bound to DNA, PDBid 4FM9.
Primary citation: Wendorff, T.J., Schmidt, B.H., Heslop, P., Austin, C.A., and
Berger, J.M. J Mol Bio, 424: 109-124, 2012. J Med Chem., 48: 2336-2345,
2005.
RSCB Protein Data Bank. Interactions between morpholinyl anthracyclines and DNA:
the crystal structure of a morpholino doxorubicin bound to d(CGTACG), PDBid
2DES. Primary citation: Cirilli, M,. Bachechi, F., Ughetto, G., Colonna, F.P.,
and Capobianco, M.L. Interactions between morpholinyl anthracyclines and
DNA: the crystal structure of a morpholino doxorubicin bound to d(CGTACG). J
Mol Biol., 230: 878-889, 1993.

188

RSCB Protein Data Bank. Structure of ellipticine in complex with a 6-bp DNA, PDBid
1Z3F. Primary citation: Canals, A., Puricolas, M., Aymami, J., and Coll, M. The
anticancer agent ellipticine unwinds DNA by intercalative binding in an
orientation parallel to base pairs. Acta Crystallogr., 61: 1009-1012, 2005.
RSCB Protein Data Bank. The crystal structure of berberine bound to DNA
d(CGTACG), PDBid 3NP6. Primary citation: Ferraroni, M., Bazzicalupi, C.,
Bilia, A.R., and Gratteri, P. X-ray diffraction analyses of the natural isoquinoline
alkaloids berberine and sanguinarine complexed with double helix DNA
d(CGTACG). Chem Commun Camb., 47: 4917-4919, 2011.
RSCB Protein Data Bank. The crystal structure of chelerythrine bound to DNA
d(CGTACG), PDBid 4D9Y. Primary citation: Ferraroni, M., Bazzicalupi, C.,
and Bilia, A.R., np.
RSCB Protein Data Bank. The crystal structure of sanguinarine bound to DNA
d(CGTACG), PDBid 3NX5. Primary citation: Ferraroni, M., Bazzicalupi, C.,
Bilia, A.R., and Gratteri, P. X-ray diffraction analyses of the natural isoquinoline
alkaloids berberine and sanguinarine complexed with double helix DNA
d(CGTACG). Chem Commun Camb., 47: 4917-4919, 2011.
Samejima K., Svingen, P.A., Basi, G.S., Kottke, T., Mesner, P.W., Stewart, L., Durrieu,
F., Poirier, G.G., Alnemri, E.S., Champoux, J.J., Kaufmann, S.H., and Earnshaw,
W.C. Caspase-mediated cleavage of DNA topoisomerase I at unconventional
sites during apoptosis. J Bio Chem., 274: 4335-4340, 1999.
Santa Cruz Biotechnology. Ellipticine (CAS 519-23-3).
<http://www.scbt.com/datasheet-200878-ellipticine.html>. Accessed June 2014.

189

Schnaith, L.M.T., Hanson, R.S., and Que, L. Double-stranded cleavage of pBR322 by a
diiron complex via a “hydrolytic” mechanism. Proc Natl Acad Sci., 91: 569-573,
1994.
Seeram, N.P., Schulman, R.N., and Heber, D, Ed. Pomegranates: ancient roots to modern
medicine. CRC Press, Taylor & Francis Group, Florida, USA, 2006.
Selvi B, R., Pradhan, S.K., Shandilya, J., Das, C., Sailaja, B.S., Shankar G, N., Gadad,
S.S., Reddy, A., Dasgupta, D., and Kundu, T.K. Sanguinarine interacts with
chromatin, modulates epigenetic modifications, and transcription in the context of
chromatin. Chem & Bio., 16(2): 203-216, 2009.
Setzer, W.N. Drugs from the cloud forest: the search for new medicines from
Monteverde, Costa Rica. Natural Products Group, University of Alabama in
Huntsville.
<http://www.uah.edu/colleges/science/chemistry/setzer/Monteverde%20Costa%2
0Rica.htm>. 2000.
Setzer, W.N. Non-intercalative triterpenoid inhibitors of topoisomerase II: A molecular
docking study. Open Bioact Compd J., 1: 13-17, 2008.
Shin, C.G., Strayer, J.M., Wani, M.A., and Snapka, R.M. Rapid evaluation of
topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo.
Teratogeneisis, Carcinogenesis, and Mutagenesis, 10: 41-52, 1990.
Sigma-Aldrich. Etoposide synthetic, ≥98%, powder. Product information,
www.sigmaaldrich.com. Accessed November 2013.
Sigma-Aldrich. Topoisomerase II α human, recombinant. Product information,
www.sigma-aldrich.com. Accessed November 2013.

190

Smith, K., Houlbrook, S., Greenall, M., Carmichael, J., and Harris, A.L. Topoisomerase
II alpha co-amplification with erbB2 in human primary breast cancer and breast
cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
Oncogene, 8(4): 933-938, 1993.
Son, J.E., Jeong, H., Kim, H., Kim, Y.A., Lee, E., Lee, H.J., and Lee, K.W. Pelargonidin
attenuates PDGF-BB-induced aortic smooth muscle cell proliferation and
migration by direct inhibition of focal adhesion kinase. Biochem Pharm., 89(2):
236-245, 2014.
Stermitz, F.R., Lorenz, P., Tawara, J.N., Zenewicz, L.A., and Lewis, K. Synergy in a
medicinal plant: antimicrobial action of berberine potentiated by 5’methoxyhydnocarpin, a multidrug pump inhibitor. PNAS, 97(4): 1433-1437,
2000.
Stiborova, M., Poljakova, J., Martinkoba, E., Borek-Dohalska, L., Eckschlager, T., Kizek,
R., and Frei, E. Ellipticine cytotoxicity to cancer cell lines–a comparative study.
Interdiscip Toxicol., 4(2): 98-105, 2011.
Suess, T.R. and Stermitz, F.R. Alkaloids of Mahonia repens with a brief review of
previous work in the genus Mahonia. J. Nat. Prod., 44(6): 680-687, 1981.
Swift, L.P., Rephaeli, A., Nudelman, A., Phillips, D.R., and Cutts, S.M. DoxorubicinDNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer
Res., 66: 4863, 2006.
Takano, H., Kohno, K., Ono, M., Uchida, Y., and Kuwano, M. Increased
phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of
human cancer KB cells. Cancer Res., 51: 3951-3957, 1991.

191

Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D., and Liu, L.F. Adriamycin-induced
DNA damage mediated by mammalian DNA topoisomerase II. Science, 226:
466-468, 1984.
The Myeloma Beacon. Doxorubicin. <http://www.myelomabeacon.com/resources/2008/
10/15/doxorubicin/>, 2008.
Thermo Scientific. pBR322. Product information, www.thermoscientific.com/onebio.
2012.
Tirabassi, R. How to identify supercoils, nicks and circles in plasmid preps.
<http://bitesizebio.com/13524/how-to-identify-supercoils-nicks-and-circles-inplasmid-preps/>, May 2014.
Traganos, F., Kapuscinski, J., and Darzynkiewicz, Z. Caffeine modulates the effects of
DNA-intercalating drugs in vitro: A flow cytometric and spectrophotometric
analysis of caffeine interaction with novantrone, doxorubicin, ellipticine, and the
doxorubicin analogue AD198. Cancer Res., 51: 3682-3689, 1991.
Traganos, F., Kapuscinski, J., Gong, J., Ardelt, B., Darzynkiewicz, R.J., and
Darzynkiewicz, Z. Caffeine prevents apoptosis and cell cycle effects induced by
camptothecin or topotecan in HL-60 cells. Cancer Res., 53: 4613-4618, 1993.
Tsuda, T., Horio, F., Uchida, K., Aoki, H., and Osawa, T. Dietary cyanidin 3-O-β-Dglucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia
in mice. J Nutr., 133(7): 2125-2130, 2003.
Walker, P. R., Smith, C., Youdale, T., Leblanc, J., Whitfield, J. F., and Sikorska, M.
Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in
thymocytes. Cancer Res., 51: 1078, 1991.

192

Wani, M.C., Ronman, P.E., Lindley, J.T., and Wall, M.E. Plant antitumor agents. 18.
Synthesis and biological activity of camptothecin analogues. J Med Chem., 23:
554-560, 1980.
Wilstermann, A. M., and Osheroff, N. Stabilization of eukaryotic topoisomerase II-DNA
cleavage complexes. Curr Top Med Chem., 3: 321-338, 2003.
Xie, H.P., Chu, X,. Jiang, J.H., Cui, H., Shen, G.L., Yu, R.Q. Competitive interactions of
adriamycin and ethidium bromide with DNA as studied by full rank parallel factor
analysis of fluorescence three-way array data. Spectrochim Acta A Mol Biomol
Spectrosc., 59(4): 743-749, 2003.
Zhang, P. Antineoplastic activity of triterpenes from Alchornea latifolia and
Dendropanax cf. querceti. Thesis submitted to the Department of Biological
Sciences and the School of Graduate Studies at the University of Alabama in
Huntsville. 1995.
Zhou, G., Wang, J., Zhao, M., Xie, T.X., Tanaka, N., Sano, D., Patel, A.A., Ward, A.M.,
Sandulache, V.C., Jasser, S.A., Skinner, H.D., Fitzgerald, A.L., Osman, A.A.,
Wei, Y., Xia, X., Songyang, Z., Mills, G.B., Hung, M.C., Caulin, C., Liang, J.,
and Myers, J.N. Gain-of-function mutant p53 promotes cell growth and cancer
cell metabolism via inhibition of AMPK activation. Mol Cell., 54: 960-974,
2014.

193

